40 results on '"Carlotta Sacerdote"'
Search Results
2. Baseline and lifetime alcohol consumption and risk of skin cancer in the European Prospective Investigation into Cancer and Nutrition cohort ( <scp>EPIC</scp> )
- Author
-
Yahya Mahamat‐Saleh, Marie Al‐Rahmoun, Gianluca Severi, Reza Ghiasvand, Marit B. Veierod, Saverio Caini, Domenico Palli, Edoardo Botteri, Carlotta Sacerdote, Fulvio Ricceri, Marko Lukic, Maria J. Sánchez, Valeria Pala, Rosario Tumino, Paolo Chiodini, Pilar Amiano, Sandra Colorado‐Yohar, María‐Dolores Chirlaque, Eva Ardanaz, Catalina Bonet, Verena Katzke, Rudolf Kaaks, Matthias B. Schulze, Kim Overvad, Christina C. Dahm, Christian S. Antoniussen, Anne Tjønneland, Cecilie Kyrø, Bas Bueno‐de‐Mesquita, Jonas Manjer, Malin Jansson, Anders Esberg, Nagisa Mori, Pietro Ferrari, Elisabete Weiderpass, Marie‐Christine Boutron‐Ruault, Marina Kvaskoff, Mahamat-Saleh, Yahya, Al-Rahmoun, Marie, Severi, Gianluca, Ghiasvand, Reza, Veierod, Marit B, Caini, Saverio, Palli, Domenico, Botteri, Edoardo, Sacerdote, Carlotta, Ricceri, Fulvio, Lukic, Marko, Sánchez, Maria J, Pala, Valeria, Tumino, Rosario, Chiodini, Paolo, Amiano, Pilar, Colorado-Yohar, Sandra, Chirlaque, María-Dolore, Ardanaz, Eva, Bonet, Catalina, Katzke, Verena, Kaaks, Rudolf, Schulze, Matthias B, Overvad, Kim, Dahm, Christina C, Antoniussen, Christian S, Tjønneland, Anne, Kyrø, Cecilie, Bueno-de-Mesquita, Ba, Manjer, Jona, Jansson, Malin, Esberg, Ander, Mori, Nagisa, Ferrari, Pietro, Weiderpass, Elisabete, Boutron-Ruault, Marie-Christine, and Kvaskoff, Marina
- Subjects
Male ,Cancer och onkologi ,Cancer Research ,Skin Neoplasms ,Alcohol Drinking ,alcohol ,keratinocyte cancers ,Public Health, Global Health, Social Medicine and Epidemiology ,Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi ,cutaneous melanoma ,cohort studies ,Oncology ,Carcinoma, Basal Cell ,Risk Factors ,Cancer and Oncology ,Carcinoma, Squamous Cell ,epidemiology ,Humans ,Female ,Prospective Studies ,Melanoma ,cohort studie - Abstract
Experimental evidence suggests that alcohol induces cutaneous carcinogenesis, yet epidemiological studies on the link between alcohol intake and skin cancer have been inconsistent. The European Prospective Investigation into Cancer and Nutrition (EPIC) is a prospective cohort initiated in 1992 in 10 European countries. Alcohol intake at baseline and average lifetime alcohol intake were assessed using validated country-specific dietary and lifestyle questionnaires. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated in Cox models. A total of 14 037 skin cancer cases (melanoma: n = 2457; basal-cell carcinoma (BCC): n = 8711; squamous-cell carcinoma (SCC): n = 1928; unknown: n = 941) were identified among 450 112 participants (average follow-up: 15 years). Baseline alcohol intake was positively associated with SCC (>15 vs 0.1-4.9 g/day: HR = 1.44, 95% CI = 1.17-1.77; Ptrend = .001), BCC (HR = 1.12, 95% CI = 1.01-1.23; Ptrend = .04), and melanoma risks in men (HR = 1.17, 95% CI = 0.95-1.44; Ptrend = .17), while associations were more modest in women (SCC: HR = 1.09, 95% CI = 0.90-1.30; Ptrend = .13; BCC: HR = 1.08, 95% CI = 1.00-1.17,Ptrend = .03; melanoma: HR = 0.93, 95% CI = 0.80-1.08, Ptrend = .13). Associations were similar for lifetime alcohol intake, with an attenuated linear trend. Lifetime liquor/spirit intake was positively associated with melanoma (fourth vs first quartile: HR = 1.47, 95% CI = 1.08-1.99; Ptrend = .0009) and BCC risks in men (HR = 1.17, 95% CI = 1.04-1.31;Ptrend = .14). Baseline and lifetime intakes of wine were associated with BCC risk (HR = 1.25 in men; HR = 1.11-1.12; in women). No statistically significant associations were found between beverage types and SCC risk. Intake of beer was not associated with skin cancer risk. Our study suggests positive relationships between alcohol intake and skin cancer risk, which may have important implications for the primary prevention of skin cancer. What's new? Drinking alcohol can make the skin more sensitive to sunlight and vulnerable to skin cancer. Here, the authors conducted a large prospective cohort study to evaluate whether alcohol consumption correlates with skin cancer risk. Among the 450 112 participants, there were 2457 cases of melanoma, 8711 of basal cell carcinoma, and 1928 of squamous cell carcinoma. There was a positive association between alcohol and all three cancer types, stronger in men than in women. The association varied somewhat by beverage type.
- Published
- 2022
3. Pregnancy outcomes and risk of endometrial cancer
- Author
-
Lauren A. Wise, Jennifer A. Doherty, Harvey A. Risch, Sara H. Olson, Louise A. Brinton, Lynne R. Wilkens, Mengmeng Du, Piet A. van den Brandt, Herbert Yu, Diego Serraino, Carlotta Sacerdote, Malcolm C. Pike, Kirsten B. Moysich, Kristin E. Anderson, Fulvio Ricceri, Timothy R. Rebbeck, Stacey Petruzella, Leo J. Schouten, Elisabete Weiderpass, Amanda B. Spurdle, Renhua Na, Rachael Z. Stolzenberg-Solomon, Fabio Levi, Susan J. Jordan, Christine M. Friedenreich, Fabio Parazzini, Anna E. Prizment, Xiao-Ou Shu, Chu Chen, Lingeng Lu, Todd R. Sponholtz, Thomas E. Rohan, Veronica Wendy Setiawan, Anthony B. Miller, Peggy Reynolds, Penelope M. Webb, Britton Trabert, Vittorio Krogh, Julie R. Palmer, Eva Negri, Wanghong Xu, Gretchen L. Gierach, Marc T. Goodman, Susan E. McCann, Immaculata De Vivo, Hans-Olov Adami, Carlo La Vecchia, Anne Zeleniuch-Jacquotte, Nicolas Wentzensen, Linda S. Cook, J. S. Jordan, R. Na, E. Weiderpa, H. O. Adami, K. E. Anderson, P. A. van den Brandt, L. A. Brinton, C. Chen, L. S. Cook, J. A. Doherty, M. Du, C. M. Friedenreich, G. L. Gierach, M. T. Goodman, V. Krogh, F. Levi, L. Lu, A. B. Miller, S. E. McCann, B. K. Moysich, E. Negri, S. H. Olson, S. Petruzella, J. R. Palmer, F. Parazzini, M. C. Pike, A. E. Prizment, T. R. Rebbeck, P. Reynold, F. Ricceri, H. A. Risch, T. E. Rohan, C. Sacerdote, L. J. Schouten, D. Serraino, V. W. Setiawan, X. -O. Shu, T. R. Sponholtz, A. B. Spurdle, R. Z. Stolzenberg-Solomon, B. Trabert, N. Wentzensen, L. R. Wilken, L. A. Wise, H. Yu, C. La Vecchia, I. De Vivo, W. Xu, A. Zeleniuch-Jacquotte, P. M. Webb, Epidemiologie, and RS: GROW - R1 - Prevention
- Subjects
Cancer Research ,medicine.medical_specialty ,miscarriage ,induced abortion ,Article ,Miscarriage ,03 medical and health sciences ,0302 clinical medicine ,AGE ,Pregnancy ,Risk Factors ,Epidemiology ,medicine ,Humans ,HORMONE-BINDING GLOBULIN ,REPRODUCTIVE FACTORS ,sex of offspring ,business.industry ,Obstetrics ,Endometrial cancer ,Pregnancy Outcome ,endometrial cancer ,parity ,WOMEN ,Odds ratio ,PROGESTERONE ,medicine.disease ,Confidence interval ,Endometrial Neoplasms ,3. Good health ,ESTROGEN ,Pooled analysis ,Oncology ,Case-Control Studies ,030220 oncology & carcinogenesis ,Cohort ,Female ,SEX ,business - Abstract
A full-term pregnancy is associated with reduced endometrial cancer risk; however, whether the effect of additional pregnancies is independent of age at last pregnancy is unknown. The associations between other pregnancy-related factors and endometrial cancer risk are less clear. We pooled individual participant data from 11 cohort and 19 case-control studies participating in the Epidemiology of Endometrial Cancer Consortium (E2C2) including 16 986 women with endometrial cancer and 39 538 control women. We used one- and two-stage meta-analytic approaches to estimate pooled odds ratios (ORs) for the association between exposures and endometrial cancer risk. Ever having a full-term pregnancy was associated with a 41% reduction in risk of endometrial cancer compared to never having a full-term pregnancy (OR = 0.59, 95% confidence interval [CI] 0.56-0.63). The risk reduction appeared the greatest for the first full-term pregnancy (OR = 0.78, 95% CI 0.72-0.84), with a further similar to 15% reduction per pregnancy up to eight pregnancies (OR = 0.20, 95% CI 0.14-0.28) that was independent of age at last full-term pregnancy. Incomplete pregnancy was also associated with decreased endometrial cancer risk (7%-9% reduction per pregnancy). Twin births appeared to have the same effect as singleton pregnancies. Our pooled analysis shows that, while the magnitude of the risk reduction is greater for a full-term pregnancy than an incomplete pregnancy, each additional pregnancy is associated with further reduction in endometrial cancer risk, independent of age at last full-term pregnancy. These results suggest that the very high progesterone level in the last trimester of pregnancy is not the sole explanation for the protective effect of pregnancy.
- Published
- 2021
4. Biomarkers of the transsulfuration pathway and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC) study
- Author
-
Joanna L. Clasen, Alicia K. Heath, Heleen Van Puyvelde, Inge Huybrechts, Jin Young Park, Pietro Ferrari, Ghislaine Scelo, Arve Ulvik, Øivind Midttun, Per Magne Ueland, Kim Overvad, Anne Kirstine Eriksen, Anne Tjønneland, Rudolf Kaaks, Verena Katzke, Matthias B. Schulze, Domenico Palli, Claudia Agnoli, Paolo Chiodini, Rosario Tumino, Carlotta Sacerdote, Raul Zamora‐Ros, Miguel Rodriguez‐Barranco, Carmen Santiuste, Eva Ardanaz, Pilar Amiano, Julie A. Schmidt, Elisabete Weiderpass, Marc Gunter, Elio Riboli, Amanda J. Cross, Mattias Johansson, David C. Muller, Clasen, J. L., Heath, A. K., Van Puyvelde, H., Huybrechts, I., Park, J. Y., Ferrari, P., Scelo, G., Ulvik, A., Midttun, O., Ueland, P. M., Overvad, K., Eriksen, A. K., Tjonneland, A., Kaaks, R., Katzke, V., Schulze, M. B., Palli, D., Agnoli, C., Chiodini, P., Tumino, R., Sacerdote, C., Zamora-Ros, R., Rodriguez-Barranco, M., Santiuste, C., Ardanaz, E., Amiano, P., Schmidt, J. A., Weiderpass, E., Gunter, M., Riboli, E., Cross, A. J., Johansson, M., Muller, D. C., and Cancer Research UK
- Subjects
Cancer Research ,dietary biomarkers ,transsulfuration ,dietary biomarker ,HOMOCYSTEINE ,METABOLISM ,urologic and male genital diseases ,vitamin B6 ,SERUM ,INFLAMMATION ,Humans ,1112 Oncology and Carcinogenesis ,ASSAY ,AMINO-ACIDS ,Oncology & Carcinogenesis ,Cysteine ,Prospective Studies ,Carcinoma, Renal Cell ,Homocysteine ,Carcinoma, Renal Cell/epidemiology ,Science & Technology ,Kidney Neoplasms/epidemiology ,PLASMA ,kidney cancer ,Bayes Theorem ,Kidney Neoplasms ,Vitamin B 6 ,Oncology ,VITAMIN-B-12 ,Case-Control Studies ,Pyridoxal Phosphate ,CYSTEINE ,Life Sciences & Biomedicine ,Biomarkers ,FOLATE - Abstract
Previous studies have suggested that components of one-carbon metabolism, particularly circulating vitamin B6, have an etiological role in renal cell carcinoma (RCC). Vitamin B6 is a cofactor in the transsulfuration pathway. We sought to holistically investigate the role of the transsulfuration pathway in RCC risk. We conducted a nested case-control study (455 RCC cases and 455 matched controls) within the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Plasma samples from the baseline visit were analyzed for metabolites of the transsulfuration pathway, including pyridoxal 5'-phosphate (PLP, the biologically active form of vitamin B6), homocysteine, serine, cystathionine, and cysteine, in addition to folate. Bayesian conditional logistic regression was used to estimate associations of metabolites with RCC risk as well as interactions with established RCC risk factors. Circulating PLP and cysteine were inversely associated with RCC risk, and these associations were not attenuated after adjustment for other transsulfuration metabolites (odds ratio (OR) and 90% credible interval (CrI) per 1 SD increase in log concentration: 0.76 [0.66, 0.87]; 0.81 [0.66, 0.96], respectively). A comparison of joint metabolite profiles suggested substantially greater RCC risk for the profile representative of low overall transsulfuration function compared to high function (OR 2.70 [90% CrI 1.26, 5.70]). We found some statistical evidence of interactions of cysteine with body mass index, and PLP and homocysteine with smoking status, on their associations with RCC risk. In conclusion, we found evidence suggesting that the transsulfuration pathway may play a role in metabolic dysregulation leading to RCC development. ispartof: INTERNATIONAL JOURNAL OF CANCER vol:151 issue:5 pages:708-716 ispartof: location:United States status: published
- Published
- 2022
5. Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition
- Author
-
Salma Butt, Rudolf Kaaks, Agnès Fournier, Marina Kvaskoff, Elisabete Weiderpass, Karolin Isaksson, Matthias B. Schulze, Susana Merino, Reza Ghiasvand, Gianluca Severi, Eva Ardanaz, Ingrid Ljuslinder, Yahya Mahamat-Saleh, Bas Bueno-de-Mesquita, Renée T. Fortner, Sandra Colorado-Yohar, Marie Al Rahmoun, Salvatore Panico, Clio Dessinioti, Sabina Sieri, Carlotta Sacerdote, Antonia Trichopoulou, Katerina Niforou, Anne Tjønneland, Laure Dossus, Ruth C. Travis, Saverio Caini, Leire Gil Majuelo, Kay-Tee Khaw, Maria J. Sánchez, Marit B. Veierød, Anja Olsen, Sabina Rinaldi, Torkjel M. Sandanger, Iris Cervenka, Malin Jansson, Marie-Christine Boutron-Ruault, Rosario Tumino, Edoardo Botteri, Domenico Palli, and Leila Lujan-Barroso
- Subjects
Oncology ,Cancer Research ,Skin Neoplasms ,Time Factors ,Dones ,hormonal treatments ,030207 dermatology & venereal diseases ,0302 clinical medicine ,cohort studies ,Risk Factors ,Surveys and Questionnaires ,Epidemiology ,Skin cancer ,Medicine ,Prospective Studies ,Prospective cohort study ,Melanoma ,oral contraceptives ,Incidence ,Estrogen Replacement Therapy ,Confounding ,Hazard ratio ,Confounding Factors, Epidemiologic ,Middle Aged ,European Prospective Investigation into Cancer and Nutrition ,Europe ,Postmenopause ,030220 oncology & carcinogenesis ,epidemiology ,Female ,Cohort study ,Adult ,medicine.medical_specialty ,menopausal hormone therapy ,Contraceptives, Oral, Hormonal ,cutaneous melanoma ,03 medical and health sciences ,Breast cancer ,Internal medicine ,Humans ,VDP::Medisinske Fag: 700 ,Women ,Nutrició ,Càncer de pell ,Aged ,Proportional Hazards Models ,Nutrition ,business.industry ,medicine.disease ,VDP::Medical disciplines: 700 ,Premenopause ,Cutaneous melanoma ,business - Abstract
This is the peer reviewed version of the following article: Cervenka, I., Al Rahmoun, M., Mahamat-Saleh, Y., Fournier, A., Boutron-Ruault, M.-C., Severi, G. ... Kvaskoff, M. (2019). Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, which has been published in final form at https://doi.org/10.1002/ijc.32674. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Evidence suggests an influence of sex hormones on cutaneous melanoma risk, but epidemiologic findings are conflicting. We examined the associations between use of oral contraceptives (OCs) and menopausal hormone therapy (MHT) and melanoma risk in women participating in the European Prospective Investigation into Cancer and Nutrition (EPIC). EPIC is a prospective cohort study initiated in 1992 in 10 European countries. Information on exogenous hormone use at baseline was derived from country‐specific self‐administered questionnaires. We used Cox proportional hazards regression models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Over 1992–2015, 1,696 melanoma cases were identified among 334,483 women, whereof 770 cases among 134,758 postmenopausal women. There was a positive, borderline‐significant association between OC use and melanoma risk (HR = 1.12, 95% CI = 1.00–1.26), with no detected heterogeneity across countries (phomogeneity = 0.42). This risk increased linearly with duration of use (ptrend = 0.01). Among postmenopausal women, ever use of MHT was associated with a nonsignificant increase in melanoma risk overall (HR = 1.14, 95% CI = 0.97–1.43), which was heterogeneous across countries (phomogeneity = 0.05). Our findings do not support a strong and direct association between exogenous hormone use and melanoma risk. In order to better understand these relations, further research should be performed using prospectively collected data including detailed information on types of hormone, and on sun exposure, which may act as an important confounder or effect modifier on these relations.
- Published
- 2019
6. Coffee and tea consumption and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition
- Author
-
Aurelio Barricarte, Tilman Kühn, Nikos Papadimitriou, Rosario Tumino, Elio Riboli, Lena Maria Nilsson, Dimitrios Trichopoulos, Dagfinn Aune, Bas Bueno-de-Mesquita, Kim Overvad, Ruth C. Travis, Nerea Larrañaga, Bodil Hammer Bech, Peter Wallström, Antonia Trichopoulou, Christina Bamia, Maria Luisa Redondo, Heiner Boeing, Valerie Cayssials, Rudolf Kaaks, Carlotta Sacerdote, Anne Tjønneland, Ioanna Tzoulaki, Neil Murphy, Anna Karakatsani, Aurora Perez-Cornago, Rikard Landberg, Anastasia Kotanidou, Cecilie Kyrø, Sara Grioni, Pagona Lagiou, Saverio Caini, David S. Lopez, Heinz Freisling, Maria Dolores Chirlaque, Amanda J. Cross, Kay-Tee Khaw, Isabel Drake, Timothy J. Key, Konstantinos K. Tsilidis, Domenico Palli, Marc J. Gunter, David C. Muller, Abhijit Sen, Malene Outzen, Manuela M. Bergmann, and María José Sánchez
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Proportional hazards model ,Incidence (epidemiology) ,Hazard ratio ,Cancer ,medicine.disease ,European Prospective Investigation into Cancer and Nutrition ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Internal medicine ,Epidemiology ,medicine ,business ,Cohort study - Abstract
The epidemiological evidence regarding the association of coffee and tea consumption with prostate cancer risk is inconclusive, and few cohort studies have assessed these associations by disease stage and grade. We examined the associations of coffee (total, caffeinated and decaffeinated) and tea intake with prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition. Among 142,196 men, 7,036 incident prostate cancer cases were diagnosed over 14 years of follow-up. Data on coffee and tea consumption were collected through validated country-specific food questionnaires at baseline. We used Cox proportional hazards regression models to compute hazard ratios (HRs) and 95% confidence intervals (CI). Models were stratified by center and age, and adjusted for anthropometric, lifestyle and dietary factors. Median coffee and tea intake were 375 and 106 mL/day, respectively, but large variations existed by country. Comparing the highest (median of 855 mL/day) versus lowest (median of 103 mL/day) consumers of coffee and tea (450 vs. 12 mL/day) the HRs were 1.02 (95% CI, 0.94–1.09) and 0.98 (95% CI, 0.90–1.07) for risk of total prostate cancer and 0.97 (95% CI, 0.79–1.21) and 0.89 (95% CI, 0.70–1.13) for risk of fatal disease, respectively. No evidence of association was seen for consumption of total, caffeinated or decaffeinated coffee or tea and risk of total prostate cancer or cancer by stage, grade or fatality in this large cohort. Further investigations are needed to clarify whether an association exists by different preparations or by concentrations and constituents of these beverages.
- Published
- 2018
7. Lifetime and baseline alcohol intakes and risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition study
- Author
-
Androniki Naska, Kim Overvad, Kuanrong Li, Eric J. Duell, Domenico Palli, Giovanna Tagliabue, Christina Bamia, Ingegerd Johansson, Petra H.M. Peeters, Nicholas J. Wareham, Anne Tjønneland, Paul Brennan, Bas Bueno-de-Mesquita, Kathryn E. Bradbury, Antonia Trichopoulou, Miguel Rodríguez-Barranco, Guri Skeie, Marie-Christine Boutron-Ruault, Salvatore Panico, Franco Berrino, Rosario Tumino, Verena Katzke, Marc J. Gunter, Sabine Naudin, Elisabete Weiderpass Vainio, Pietro Ferrari, Inger T. Gram, Anne Laure Védié, Elio Riboli, Aurelio Barricarte, Miren Dorronsoro, Nada Assi, Tristan Jaouen, José Ramón Quirós, Rudolf Kaaks, Heiner Boeing, Maria Dolores Chirlaque, Malin Sund, Hanna Sternby, Carlotta Sacerdote, Vinciane Rebours, and Cecilie Kyrø
- Subjects
0301 basic medicine ,Cancer Research ,business.industry ,Hazard ratio ,Alcohol ,medicine.disease ,Confidence interval ,European Prospective Investigation into Cancer and Nutrition ,03 medical and health sciences ,chemistry.chemical_compound ,030104 developmental biology ,0302 clinical medicine ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Pancreatic cancer ,Medicine ,Smoking status ,business ,Prospective cohort study ,Wine intake ,Demography - Abstract
Recent evidence suggested a weak relationship between alcohol consumption and pancreatic cancer (PC) risk. In our study, the association between lifetime and baseline alcohol intakes and the risk of PC was evaluated, including the type of alcoholic beverages and potential interaction with smoking. Within the European Prospective Investigation into Cancer and Nutrition (EPIC) study, 1,283 incident PC (57% women) were diagnosed from 476,106 cancer-free participants, followed up for 14 years. Amounts of lifetime and baseline alcohol were estimated through lifestyle and dietary questionnaires, respectively. Cox proportional hazard models with age as primary time variable were used to estimate PC hazard ratios (HR) and their 95% confidence interval (CI). Alcohol intake was positively associated with PC risk in men. Associations were mainly driven by extreme alcohol levels, with HRs comparing heavy drinkers (>60 g/day) to the reference category (0.1-4.9 g/day) equal to 1.77 (95% CI: 1.06, 2.95) and 1.63 (95% CI: 1.16, 2.29) for lifetime and baseline alcohol, respectively. Baseline alcohol intakes from beer (>40 g/day) and spirits/liquors (>10 g/day) showed HRs equal to 1.58 (95% CI: 1.07, 2.34) and 1.41 (95% CI: 1.03, 1.94), respectively, compared to the reference category (0.1-2.9 g/day). In women, HR estimates did not reach statistically significance. The alcohol and PC risk association was not modified by smoking status. Findings from a large prospective study suggest that baseline and lifetime alcohol intakes were positively associated with PC risk, with more apparent risk estimates for beer and spirits/liquors than wine intake.
- Published
- 2018
8. Prospective evaluation of antibody response toStreptococcus gallolyticusand risk of colorectal cancer
- Author
-
Kathryn E. Bradbury, Carlo La Vecchia, Elisabete Weiderpass, Domenico Palli, Dagfinn Aune, Gianluca Severi, Eva Ardanaz, Michael Pawlita, Salvatore Panico, José María Huerta, H. Bas Bueno-de-Mesquita, María José Sánchez, Martina Willhauck-Fleckenstein, Anna Karakatsani, Kostas Tsilidis, Rosario Tumino, Franck Carbonnel, Marc J. Gunter, Angelika Michel, Carlotta Sacerdote, Mazda Jenab, Cecilie Kyrø, Heinz Freisling, Heiner Boeing, Claudia Agnoli, Rudolf Kaaks, Antonia Trichopoulou, Elio Riboli, Julia Butt, David J. Hughes, Tim Waterboer, Anne Tjønneland, Tilman Kühn, Catalina Bonet, Neil Murphy, and Marie-Christine Boutron-Ruault
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,biology ,Colorectal cancer ,business.industry ,Case-control study ,Cancer ,Odds ratio ,medicine.disease ,Gastroenterology ,Serology ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,biology.protein ,Streptococcus gallolyticus ,Antibody ,business ,Prospective cohort study - Abstract
The gut microbiome is increasingly implicated in colorectal cancer (CRC) development. A subgroup of patients diagnosed with CRC show high antibody responses to Streptococcus gallolyticus subspecies gallolyticus (SGG). However, it is unclear whether the association is also present pre-diagnostically. We assessed the association of antibody responses to SGG proteins in pre-diagnostic serum samples with CRC risk in a case-control study nested within a prospective cohort. Pre-diagnostic serum samples from 485 first incident CRC cases (mean time between blood draw and diagnosis 3.4 years) and 485 matched controls in the European Prospective Investigation into Nutrition and Cancer (EPIC) study were analyzed for antibody responses to 11 SGG proteins using multiplex serology. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using multivariable conditional logistic regression models. Antibody positivity for any of the 11 SGG proteins was significantly associated with CRC risk with 56% positive controls compared to 63% positive cases (OR: 1.36, 95% CI: 1.04-1.77). Positivity for two or more proteins of a previously identified SGG 6-marker panel with greater CRC-specificity was also observed among 9% of controls compared to 17% of CRC cases, corresponding to a significantly increased CRC risk (OR: 2.17, 95% CI: 1.44-3.27). In this prospective nested case-control study, we observed a positive association between antibody responses to SGG and CRC development in serum samples taken before evident disease onset. Further work is required to establish the possibly etiological significance of these observations and whether SGG serology may be applicable for CRC risk stratification.
- Published
- 2018
9. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort
- Author
-
Petra H.M. Peeters, Anika Hüsing, Marina Kvaskoff, Hidemi S. Yamamoto, Eva Lundin, Carlotta Sacerdote, Elio Riboli, Renée T. Fortner, Louise Hansen, Elisabete Weiderpass, Heiner Boeing, Daniel W. Cramer, J. Ramón Quirós, Gianluca Severi, Kathryn L. Terry, Amalia Mattiello, Eric J. Duell, Rosario Tumino, Eva Ardanaz, Helena Schock, Titilayo Fashemi, Björn Nodin, Ruth C. Travis, Anne Tjønneland, Kim Overvad, Annika Idahl, Laure Dossus, Carmen Navarro, H B As Bueno-de-Mesquita, Carlo La Vecchia, Marie-Christine Boutron-Ruault, Allison F. Vitonis, Nerea Larrañaga, María José Sánchez, Domenico Palli, Marc J. Gunter, Karin Jirström, Antonia Trichopoulou, Charlotte Le Cornet, Mattias Johansson, Raina N. Fichorova, Kay-Tee Khaw, N. Charlotte Onland-Moret, Theron Johnson, Melissa A. Merritt, Sabina Sieri, Eleni-Maria Papatesta, and Rudolf Kaaks
- Subjects
0301 basic medicine ,Oncology ,endocrine system ,Cancer Research ,medicine.medical_specialty ,endocrine system diseases ,Context (language use) ,EPIC ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Ovarian cancer early detection ,business.industry ,Autoantibody ,Case-control study ,medicine.disease ,female genital diseases and pregnancy complications ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cohort ,Immunology ,business ,Ovarian cancer ,Cohort study - Abstract
CA125 is the best ovarian cancer early detection marker to date; however, sensitivity is limited and complementary markers are required to improve discrimination between ovarian cancer cases and no ...
- Published
- 2017
10. Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts
- Author
-
Elisabete Weiderpass, Eva Lundin, Shelley S. Tworoger, Naomi E. Allen, Louise A. Brinton, Aurelio Barricarte, Ruth C. Travis, Annika Idahl, Helena Schock, Seungyoun Jung, Roni T. Falk, Kala Visvanathan, Melissa A. Merritt, Sabina Rinaldi, Yu-Tang Gao, Kathy J. Helzlsouer, Joanne F. Dorgan, Antonia Trichopoulou, Carlotta Sacerdote, Laura Baglietto, Vittorio Krogh, Renée T. Fortner, Patrick M. Sluss, Paul N. Staats, Alan A. Arslan, Brian L. Egleston, Xiao-Ou Shu, N. Charlotte Onland-Moret, Rudolph Kaaks, Anne Zeleniuch-Jacquotte, and Anne Tjønneland
- Subjects
0301 basic medicine ,Oncology ,endocrine system ,Cancer Research ,medicine.medical_specialty ,endocrine system diseases ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Young adult ,Ovarian reserve ,biology ,business.industry ,Case-control study ,Anti-Müllerian hormone ,Odds ratio ,medicine.disease ,female genital diseases and pregnancy complications ,030104 developmental biology ,030220 oncology & carcinogenesis ,biology.protein ,Adenocarcinoma ,Ovarian cancer ,business ,Cohort study - Abstract
Animal and experimental data suggest that anti-Mullerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 302 ovarian cancer cases and 336 matched controls from nine cohorts. Prediagnostic blood samples of premenopausal women were assayed for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable-adjusted conditional logistic regression. AMH concentration was not associated with overall ovarian cancer risk. The multivariable-adjusted OR (95% CI), comparing the highest to the lowest quartile of AMH, was 0.99 (0.59-1.67) (Ptrend : 0.91). The association did not differ by age at blood draw or oral contraceptive use (all Pheterogeneity : ≥0.26). There also was no evidence for heterogeneity of risk for tumors defined by histologic developmental pathway, stage, and grade, and by age at diagnosis and time between blood draw and diagnosis (all Pheterogeneity : ≥0.39). In conclusion, this analysis of mostly late premenopausal women from nine cohorts does not support the hypothesized inverse association between prediagnostic circulating levels of AMH and risk of ovarian cancer.
- Published
- 2017
11. An estimate of the number of people in Italy living after a childhood cancer
- Author
-
Stefano Guzzinati, Ettore Bidoli, Luigino Dal Maso, Lucia Mangone, Giovanna Tagliabue, MILENA MARIA MAULE, Stefano Ferretti, Anna Gigli, Gemma Gatta, Carlotta Sacerdote, Silvia Francisci, and Fabio Falcini
- Subjects
Cancer Research ,Cancer survivor ,Pediatrics ,medicine.medical_specialty ,business.industry ,Incidence (epidemiology) ,Late effect ,Cancer ,medicine.disease ,Quarter (United States coin) ,Cancer registry ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Health care ,medicine ,030212 general & internal medicine ,medicine.symptom ,business ,Survival rate - Abstract
Cancers diagnosed in children below the age of 15 years represent 1.2% of all cancer cases, and survival after a childhood cancer has greatly improved over the past 40 years in all high income countries. This study aims to estimate the number of people living in Italy after a childhood cancer for all cancers combined and for a selection of cancer types. We computed 15-year prevalence using data from 15 Italian population-based cancer registries (covering 19% of Italian population) and estimated complete prevalence for Italy by using the CHILDPREV method, implemented in the COMPREV software. A total of 44,135 persons were alive at January 1st, 2010 after a cancer diagnosed during childhood. This number corresponds to a proportion of 73 per 100,000 Italians and to about 2% of all prevalent cases. Among them, 54% were males and 64% had survived after being diagnosed before 1995, the start of the observation period. A quarter of all childhood prevalent cases were diagnosed with brain and central nervous system tumors, a quarter with acute lymphoid leukemia, and 7% with Hodgkin lymphoma. Nearly a quarter of prevalent patients were aged 40 years and older. Information about the number of people living after a childhood cancer in Italy by cancer type and their specific health care needs may be helpful to health-care planners and clinicians in the development of guidelines aimed to reduce the burden of late effect of treatments during childhood.
- Published
- 2017
12. Coffee, tea and melanoma risk: findings from the European Prospective Investigation into Cancer and Nutrition
- Author
-
Emily Sonestedt, Marc J. Gunter, Karin Jirström, Inge Huybrechts, Antonia Trichopoulou, Tilman Kühn, Neil Murphy, Rudolf Kaaks, Petra H.M. Peeters, Giovanna Tagliabue, Elisabete Weiderpass, Isabelle Savoye, Calogero Saieva, H. Bas Bueno-de-Mesquita, Oskar Hemmingsson, Elisavet Valanou, Marie-Christine Boutron-Ruault, Kristina E.N. Petersen, Reza Ghiasvand, Kim Overvad, Maria Kritikou, Salvatore Panico, Marko Lukic, Lena Maria Nilsson, Eva Ardanaz, Saverio Caini, Nerea Larrañaga, Bodil Hammer Bech, Marina Kvaskoff, Domenico Palli, Anne Tjønneland, Kay-Tee Khaw, Ingrid Ljuslinder, Marit B. Veierød, Nicholas J. Wareham, Raul Zamora-Ros, Francesca Mancini, Maria Dolores Chirlaque, Heiner Boeing, Elena Salamanca Fernández, Carlotta Sacerdote, Timothy J. Key, Iris Cervenka, Rosario Tumino, Anna Floegel, Konstantinos K. Tsilidis, José Ramón Quirós, and Giovanna Masala
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,business.industry ,Hazard ratio ,Surgery ,European Prospective Investigation into Cancer and Nutrition ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,Quartile ,030220 oncology & carcinogenesis ,Environmental health ,Epidemiology ,Cutaneous melanoma ,medicine ,business ,Risk assessment ,Prospective cohort study ,Cohort study - Abstract
In vitro and animal studies suggest that bioactive constituents of coffee and tea may have anticarcinogenic effects against cutaneous melanoma; however, epidemiological evidence is limited to date. We examined the relationships between coffee (total, caffeinated or decaffeinated) and tea consumption and risk of melanoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). EPIC is a multicentre prospective study that enrolled over 500,000 participants aged 25–70 years from ten European countries in 1992–2000. Information on coffee and tea drinking was collected at baseline using validated country-specific dietary questionnaires. We used adjusted Cox proportional hazards regression models to calculate hazard ratios (HR) and 95% confidence intervals (95% CI) for the associations between coffee and tea consumption and melanoma risk. Overall, 2,712 melanoma cases were identified during a median follow-up of 14.9 years among 476,160 study participants. Consumption of caffeinated coffee was inversely associated with melanoma risk among men (HR for highest quartile of consumption vs. non-consumers 0.31, 95% CI 0.14–0.69) but not among women (HR 0.96, 95% CI 0.62–1.47). There were no statistically significant associations between consumption of decaffeinated coffee or tea and the risk of melanoma among both men and women. The consumption of caffeinated coffee was inversely associated with melanoma risk among men in this large cohort study. Further investigations are warranted to confirm our findings and clarify the possible role of caffeine and other coffee compounds in reducing the risk of melanoma.
- Published
- 2017
13. Abdominal adiposity is not a mediator of the protective effect of Mediterranean diet on colorectal cancer
- Author
-
Daniela Zugna, Graziella Frasca, Salvatore Panico, Vittorio Krogh, Fulvio Ricceri, Rosario Tumino, Saverio Caini, Giovanna Masala, Maria Teresa Giraudo, Veronica Sciannameo, Francesca Fasanelli, Sara Grioni, Carlotta Sacerdote, and Amalia Mattiello
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Mediterranean diet ,business.industry ,Hazard ratio ,Odds ratio ,European Prospective Investigation into Cancer and Nutrition ,03 medical and health sciences ,0302 clinical medicine ,Waist–hip ratio ,Endocrinology ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,030212 general & internal medicine ,medicine.symptom ,Prospective cohort study ,business ,Body mass index ,Abdominal obesity - Abstract
Adherence to the Mediterranean diet (MD) has a preventive effect on colorectal cancer (CRC). Several biological mechanisms have been hypothesized to explain this effect, but the involvement of clinical mediators has not been experimentally proven. We examined the role of abdominal adiposity (i.e., waist-to-hip ratio, WHR) as a potential mediator of the relationship between the MD and CRC in the Italian centres of the European Prospective Investigation into Cancer and Nutrition. We evaluated the effect of the Italian Mediterranean Index (IMI) on WHR and of WHR on CRC risk. We then estimated the natural indirect effect (NIE, mediated by WHR) and the pure direct effect (PDE, unmediated) of IMI on CRC risk using mediation analyses, considering age, sex, education, physical activity, smoking and EPIC centre as confounders. Increased IMI was associated with significantly decreased odds of high WHR (odds ratio [OR] for an IMI of 6-11 vs. 0-1: 0.88, 95% confidence interval [CI]: 0.81-0.97). There was a positive relationship between WHR and CRC (hazard ratio [HR] for high vs. low WHR: 1.34, 95%CI: 1.09-1.66). The total effect of IMI was protective on CRC risk and was mainly explained by the PDE (HR for an IMI of 6-11 vs. 0-1: 0.51, 95%CI: 0.31-0.83), whereas the NIE was 1.00 (95%CI: 0.94-1.10). In this Mediterranean cohort, the protective effect of the MD on the development of CRC was not mediated by abdominal adiposity. Since this is the first study to investigate the mediating effect of abdominal obesity, other studies are needed to replicate this result.
- Published
- 2017
14. Endometrial cancer risk prediction including serum-based biomarkers: results from the EPIC cohort
- Author
-
Kim Overvad, Marc J. Gunter, Inger T. Gram, Giovanna Masala, Agnès Fournier, Salma Butt, Kay-Tee Khaw, J. Ramón Quirós, Sabina Rinaldi, Carlotta Sacerdote, Tilman Kühn, José María Huerta, Meric Konar, H. Bas Bueno-de-Mesquita, Gianluca Severi, Renée T. Fortner, Eva Ardanaz, Leila Lujan-Barroso, Claudia Agnoli, Vasiliki Benetou, Rosario Tumino, Amalia Mattiello, Anika Hüsing, Oxana Gavrilyuk, Marie-Christine Boutron-Ruault, Elio Riboli, Antonia Trichopoulou, Rudolf Kaaks, Nerea Larrañaga, Petra H.M. Peeters, Eva Lundin, Emilio Sánchez-Cantalejo, Elisabete Weiderpass, Louise Hansen, Signe Borgquist, Ioanna Tzoulaki, Philippos Orfanos, Naomi E. Allen, Annika Idahl, Melissa A. Merritt, Anne Tjønneland, Laure Dossus, and Heiner Boeing
- Subjects
0301 basic medicine ,Gynecology ,Oncology ,Cancer Research ,medicine.medical_specialty ,Adiponectin ,business.industry ,Endometrial cancer ,Absolute risk reduction ,Adipokine ,medicine.disease ,3. Good health ,European Prospective Investigation into Cancer and Nutrition ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,Cohort ,medicine ,Biomarker (medicine) ,10. No inequality ,business ,Prospective cohort study - Abstract
Endometrial cancer risk prediction models including lifestyle, anthropometric and reproductive factors have limited discrimination. Adding biomarker data to these models may improve predictive capacity; to our knowledge, this has not been investigated for endometrial cancer. Using a nested case–control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we investigated the improvement in discrimination gained by adding serum biomarker concentrations to risk estimates derived from an existing risk prediction model based on epidemiologic factors. Serum concentrations of sex steroid hormones, metabolic markers, growth factors, adipokines and cytokines were evaluated in a step-wise backward selection process; biomarkers were retained at p
- Published
- 2017
15. Outdoor air pollution and risk for kidney parenchyma cancer in 14 European cohorts
- Author
-
Johan Nilsson Sommar, Anne Tjønneland, Petra H.M. Peeters, Paolo Vineis, Nancy L. Pedersen, Ingeborg M. Kooter, Marloes Eeftens, Carlotta Sacerdote, Alessandro Marcon, Marie Pedersen, Claudia Galassi, Massimo Stafoggia, Andrea Jaensch, Enrica Migliore, Kirsten Thorup Eriksen, Andrei Pyko, Rob Beelen, Laura Fratiglioni, Ranjeet S. Sokhi, Bertil Forsberg, Gerard Hoek, Ming-Yi Tsai, Fulvio Ricceri, Miren Dorronsoro, Gunn Marit Aasvang, H. Bas Bueno-de-Mesquita, Meng Wang, Bernhard Föger, Zorana Jovanovic Andersen, Ulf de Faire, Kees de Hoogh, Gudrun Weinmayr, Sara Grioni, Mette Sørensen, Claes-Göran Östenson, Roel Vermeulen, Pilar Amiano, Ibon Tamayo, Michelle Plusquin, Norun Hjertager Krog, Göran Pershagen, Timothy J. Key, David Olsson, Gabriele Nagel, Bert Brunekreef, Ole Raaschou-Nielsen, Michal Korek, Vittorio Krogh, and Bente Oftedal
- Subjects
Pollutant ,Cancer Research ,business.industry ,Air pollution ,Cancer ,Environmental exposure ,010501 environmental sciences ,Particulates ,medicine.disease ,medicine.disease_cause ,complex mixtures ,01 natural sciences ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Environmental health ,Parenchyma ,medicine ,business ,Risk assessment ,Kidney cancer ,0105 earth and related environmental sciences - Abstract
Several studies have indicated weakly increased risk for kidney cancer among occupational groups exposed to gasoline vapors, engine exhaust, polycyclic aromatic hydrocarbons and other air pollutant ...
- Published
- 2017
16. Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses
- Author
-
Fatemeh Saberi Hosnijeh, Giovanna Masala, Beatrice Melin, Paolo Vineis, Alessio Naccarati, Ingvar A. Bergdahl, Lützen Portengen, Florentin Späth, Rosario Tumino, Carlotta Sacerdote, Amalia Mattiello, Roel Vermeulen, Marc Chadeau-Hyam, and Vittorio Krogh
- Subjects
0301 basic medicine ,Cancer Research ,education.field_of_study ,business.industry ,Population ,Follicular lymphoma ,Case-control study ,Odds ratio ,medicine.disease ,Lymphoma ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Nested case-control study ,Immunology ,medicine ,Prospective cohort study ,business ,education ,B cell - Abstract
Prediagnostic serum/plasma concentrations of B-cell activation markers have been associated with future risk of B-cell lymphomas (BCL) in HIV-infected patients and in the general population. Current evidence for the general population is however limited and relies on relatively small numbers of observations, especially for specific histologies. We carried out a nested case-control study, including 218 BCL and 218 matched controls, within two prospective cohorts, to investigate the association between plasma levels of soluble (s)CD27 and sCD30 and future risk of BCL, and main histologic subtypes separately. To expand the evidence further, we performed meta-analyses of the published data on these associations from prospective studies among the general population. Our study revealed a significant relationship between sCD30 concentration and BCL risk (OR = 0.86, 1.53, 1.76, for the 2nd-4th quartiles respectively, p trend = 0.01). Similar increased risks were observed for diffuse large B-cell lymphoma and follicular lymphoma. Analyses of sCD27 blood concentrations did not show significant associations with BCL, (OR = 0.90, 1.26, 1.65 for the 2nd-4th quartiles, respectively, p trend = 0.17), but significant associations were observed for chronic lymphocytic leukaemia and for the group of "other BCL" subtypes. Our findings involving sCD30 were confirmed within our meta-analyses of five prospective cohorts, while results were more heterogeneous for sCD27 with the exception of CLL which was found consistently in all studies. Data to date suggest that chronic B-cell stimulation might be an important mechanism involved in B-cell lymphomagenesis both in HIV-infected and in the general population.
- Published
- 2016
17. Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: Results from the EPIC cohort
- Author
-
Isabelle Romieu, Amalia Mattiello, Kay-Tee Khaw, Pagona Lagiou, Marc J. Gunter, Kim Overvad, Inger T. Gram, Petra H.M. Peeters, Eva Lundin, Giovanna Masala, Louise Hansen, Vassiliki Benetou, Eva Ardanaz, Jenny Brändstedt, Françoise Clavel-Chapelon, M-D Chirlaque, H. B. Bueno-De-Mesquita, Eric J. Duell, Nerea Larrañaga, María José Sánchez, Rosario Tumino, Ruth C. Travis, N. Charlotte Onland-Moret, Elio Riboli, Claudia Agnoli, Helena Schock, Carlotta Sacerdote, Antonia Trichopoulou, Laura Baglietto, Elisabete Weiderpass, Nicholas J. Wareham, Annika Idahl, Melissa A. Merritt, Jennifer Ose, Renée T. Fortner, Heiner Boeing, Anne Tjønneland, Sabina Rinaldi, Laure Dossus, and Rudolf Kaaks
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,endocrine system diseases ,business.industry ,Endometrial cancer ,Cancer ,medicine.disease ,female genital diseases and pregnancy complications ,European Prospective Investigation into Cancer and Nutrition ,Serous fluid ,Internal medicine ,Relative risk ,medicine ,Risk factor ,business ,Ovarian cancer ,Prospective cohort study - Abstract
Whether risk factors for epithelial ovarian cancer (EOC) differ by subtype (i.e., dualistic pathway of carcinogenesis, histologic subtype) is not well understood; however, data to date suggest risk factor differences. We examined associations between reproductive and hormone-related risk factors for EOC by subtype in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Among 334,126 women with data on reproductive and hormone-related risk factors (follow-up: 1992-2010), 1,245 incident cases of EOC with known histology and invasiveness were identified. Data on tumor histology, grade, and invasiveness, were available from cancer registries and pathology record review. We observed significant heterogeneity by the dualistic model (i.e., type I [low grade serous or endometrioid, mucinous, clear cell, malignant Brenner] vs. type II [high grade serous or endometrioid]) for full-term pregnancy (p(het)=0.02). Full-term pregnancy was more strongly inversely associated with type I than type II tumors (ever vs. never: type I: relative risk (RR) 0.47 [95% confidence interval (CI): 0.33-0.69]; type II, RR: 0.81 [0.61-1.06]). We observed no significant differences in risk in analyses by major histologic subtypes of invasive EOC (serous, mucinous, endometrioid, clear cell). None of the investigated factors were associated with borderline tumors. Established protective factors, including duration of oral contraceptive use and full term pregnancy, were consistently inversely associated with risk across histologic subtypes (e.g., ever full-term pregnancy: serous, RR: 0.73 [0.58-0.92]; mucinous, RR: 0.53 [0.30-0.95]; endometrioid, RR: 0.65 [0.40-1.06]; clear cell, RR: 0.34 [0.18-0.64]; p(het)=0.16). These results suggest limited heterogeneity between reproductive and hormone-related risk factors and EOC subtypes. What's new? Reproductive and hormone-related risk factors for epithelial ovarian cancer (EOC) have been extensively investigated. However, EOC is increasingly recognized as a heterogeneous disease and risk factor differences across EOC subtypes, as defined by the recently proposed dualistic pathway of ovarian carcinogenesis and histological characteristics, are not well understood. Here, the authors present a detailed prospective investigation on reproductive and hormone-related risk factors for borderline tumors and epithelial ovarian cancer by main histological subtypes and, for the first time, by the types defined by the dualistic pathway. The results suggest limited heterogeneity between reproductive and hormone-related risk factors and EOC subtypes.
- Published
- 2015
18. Risk of second primary malignancies in women with breast cancer: Results from the European prospective investigation into cancer and nutrition (EPIC)
- Author
-
Paolo Vineis, Sabina Sieri, Kay-Tee Khaw, Anne Tjønneland, Petra H.M. Peeters, Laure Dossus, Sabina Rinaldi, J. Ramón Quirós, Françoise Clavel-Chapelon, Marina Kvaskoff, Salma Butt, Eva Ardanaz, Heiner Boeing, Vassiliki Benetou, Guri Skeie, Anne Andersson, Anja Olsen, Malin Sund, María Dolores Chirlaque, George Adarakis, Maria Teresa Giraudo, Signe Borgquist, Noémie Travier, Elio Riboli, Mai Kadi, Francesca Fasanelli, Fulvio Ricceri, Rosario Tumino, Isabelle Romieu, Elisabete Weiderpass, Rudolf Kaaks, Jenny Chang-Claude, Kim Overvad, H. Bas Bueno-de-Mesquita, Liliana Vagliano, Amalia Mattiello, Antonia Trichopoulou, Carlotta Sacerdote, Giovanna Masala, Marc J. Gunter, María José Sánchez, Nerea Larrañaga, and Ruth C. Travis
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Endometrial cancer ,Absolute risk reduction ,Cancer ,medicine.disease ,European Prospective Investigation into Cancer and Nutrition ,Breast cancer ,Risk factors for breast cancer ,Internal medicine ,Epidemiology of cancer ,medicine ,business ,Screening procedures - Abstract
Women with a diagnosis of breast cancer are at increased risk of second primary cancers, and the identification of risk factors for the latter may have clinical implications. We have followed-up for 11 years 10,045 women with invasive breast cancer from a European cohort, and identified 492 second primary cancers, including 140 contralateral breast cancers. Expected and observed cases and Standardized Incidence Ratios (SIR) were estimated using Aalen-Johansen Markovian methods. Information on various risk factors was obtained from detailed questionnaires and anthropometric measurements. Cox proportional hazards regression models were used to estimate the role of risk factors. Women with breast cancer had a 30% excess risk for second malignancies (95% confidence interval-CI 18-42) after excluding contralateral breast cancers. Risk was particularly elevated for colorectal cancer (SIR, 1.71, 95% CI 1.43-2.00), lymphoma (SIR 1.80, 95% CI 1.31-2.40), melanoma (2.12; 1.63-2.70), endometrium (2.18; 1.75-2.70) and kidney cancers (2.40; 1.57-3.52). Risk of second malignancies was positively associated with age at first cancer, body mass index and smoking status, while it was inversely associated with education, post-menopausal status and a history of full-term pregnancy. We describe in a large cohort of women with breast cancer a 30% excess of second primaries. Among risk factors for breast cancer, a history of full-term pregnancy was inversely associated with the risk of second primary cancer. What's new? For the first time, researchers have used cohort data to show that people who survive breast cancer have a higher risk of developing another cancer later. By collecting data on 10,000 breast cancer patients over 11 years, these authors calculated a 30% boost in the patients' risk of developing a second primary malignancy, particularly colorectal cancer, lymphoma, melanoma, endometrial cancer, and kidney cancer. These findings, plus the data they collected on risk factors such as age, smoking, body mass index, and others, will help guide clinicians in screening procedures and follow up care for breast cancer patients.
- Published
- 2015
19. Dietary glycemic index and glycemic load and risk of colorectal cancer: results from the EPIC-Italy study
- Author
-
Francesca Scazzina, Fulvio Ricceri, Giovanna Masala, R. Tumino, Carlotta Sacerdote, Vittorio Krogh, Domenico Palli, Maria Concetta Giurdanella, Claudia Agnoli, Sabina Sieri, Paolo Vineis, A. Mattiello, Furio Brighenti, and Salvatore Panico
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Colorectal cancer ,Insulin ,medicine.medical_treatment ,Hazard ratio ,Cancer ,medicine.disease ,Gastroenterology ,Confidence interval ,Endocrinology ,Glycemic index ,Oncology ,Internal medicine ,parasitic diseases ,Glycemic load ,Cohort ,medicine ,population characteristics ,business ,human activities - Abstract
A carbohydrate-rich diet, resulting in high blood glucose and insulin, has been hypothesized as involved in colorectal cancer etiology. We investigated dietary glycemic index (GI) and glycemic load (GL), in relation to colorectal cancer, in the prospectively recruited EPIC-Italy cohort. After a median 11.7 years, 421 colorectal cancers were diagnosed among 47,749 recruited adults. GI and GL were estimated from validated food frequency questionnaires. Multivariable Cox modeling estimated hazard ratios (HRs) for associations between colorectal cancer and intakes of total, high GI and low GI carbohydrate and GI and GL. The adjusted HR of colorectal cancer for highest versus lowest GI quartile was 1.35; 95% confidence interval (CI) 1.03-1.78; p trend 0.031. Increasing high GI carbohydrate intake was also significantly associated with increasing colorectal cancer risk (HR 1.45; 95% CI 1.04-2.03; p trend 0.034), whereas increasing low GI carbohydrate was associated with reducing risk (HR 0.73; 95% CI 0.54-0.98; p trend 0.033). High dietary GI and high GI carbohydrate were associated with increased risks of cancer at all colon sites (HR 1.37; 95% CI 1.00-1.88, HR 1.80; 95% CI 1.22-2.65, respectively), whereas high GI carbohydrate and high GL were associated with increased risk of proximal colon cancer (HR 1.94; 95% CI 1.18-3.16, HR 2.01; 95% CI 1.08-3.74, respectively). After stratification for waist-to-hip ratio (WHR), cancer was significantly associated with GI, and high GI carbohydrate, in those with high WHR. These findings suggest that high dietary GI and high carbohydrate intake from high GI foods are associated with increased risk of colorectal cancer.
- Published
- 2014
20. Meat and fish consumption and the risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition
- Author
-
Paula Jakszyn, Marie-Christine Boutron-Ruault, Börje Ljungberg, Guri Skeie, Esther Molina-Montes, Steffen Weikert, Mattias Johansson, Kim Overvad, Claudia Agnoli, Tilman Kühn, Nadia Bastide, Rosario Tumino, Ulrika Ericson, Amanda J. Cross, Petra H.M. Peeters, Nicholas J. Wareham, Antonia Trichopoulou, Jakob Linseisen, Anne Tjønneland, Kuanrong Li, Domenico Palli, Emily Sonestedt, Nina Roswall, Elisabete Weiderpass, Anette Hjartåker, H. Bas Bueno-de-Mesquita, Ramón Alonso De La Torre, Kathryn E. Bradbury, Kay-Tee Khaw, Carlotta Sacerdote, Salvatore Panico, Annika Steffen, Dimitrios Trichopoulos, Anne-Claire Vergnaud, Antoine Racine, Isabelle Romieu, Sabine Rohrmann, Heinz Freisling, Elio Riboli, Anne Mette Lund Würtz, Aurelio Barricarte, Eleni Peppa, Heiner Boeing, Miren Dorronsoro, and Carmen Santiuste De Pablos
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Incidence (epidemiology) ,Hazard ratio ,medicine.disease ,European Prospective Investigation into Cancer and Nutrition ,Surgery ,Oncology ,Renal cell carcinoma ,Internal medicine ,Epidemiology ,Red meat ,Medicine ,business ,Kidney cancer ,Cohort study - Abstract
Renal cell cancer (RCC) incidence varies worldwide with a higher incidence in developed countries and lifestyle is likely to contribute to the development of this disease. We examined whether meat and fish consumption were related to the risk of RCC in the European Prospective Investigation into Cancer and Nutrition (EPIC). The analysis included 493,179 EPIC participants, recruited between 1992 and 2000. Until December 2008, 691 RCC cases have been identified. Meat and fish consumption was assessed at baseline using country-specific dietary assessment instruments; 24-hour recalls were applied in an 8% subsample for calibration purposes. Cox proportional hazards regression was used to calculate multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CI). Women with a high consumption of red meat (HR=1.36, 95% CI 1.14-1.62; calibrated, per 50 g/day) and processed meat (HR=1.78, 95% CI 1.05-3.03; calibrated, per 50 g/day) had a higher risk of RCC, while no association existed in men. For processed meat, the association with RCC incidence was prominent in premenopausal women and was lacking in postmenopausal women (p interaction=0.02). Neither poultry nor fish consumption were statistically significantly associated with the risk of RCC. The results show a distinct association of red and processed meat consumption with incident RCC in women but not in men. A biological explanation for these findings remains unclear. What's new? Kidney cancer strikes different populations with different frequency, with developed nations seeing more cases. In this paper, the authors investigate whether certain elements of diet might correlate with increased incidence of renal cell carcinoma. Using data from the European Prospective Investigation into Cancer and Nutrition (EPIC), they assessed the amount of meat and fish consumed in populations representing a wide range of dietary habits. They then correlated this data with renal cell carcinoma incidence. They found no effect from eating fish; consuming red and processed meats did increase risk in women, but not in men.
- Published
- 2014
21. Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition
- Author
-
Renée T. Fortner, Eiliv Lund, Rudolf Kaaks, Aurelio Barricarte, Pagona Lagiou, Elisabete Weiderpass, Elisabetta Kuhn, Kay Tee Kaw, Helena Schock, Annika Idahl, Agnès Fournier, Anne Tjønneland, Heiner Boeing, Laure Dossus, Rosario Tumino, Amalia Mattiello, José Ramón Quirós, Mireia Obón-Santacana, Kim Overvad, Eva Lundin, Carlotta Sacerdote, Antonia Trichopoulou, Louise Hansen, Nerea Larrañaga, N. Charlotte Onland-Moret, Isabelle Romieu, Dimitrios Trichopoulos, Laura Baglietto, Sabina Rinaldi, Marc J. Gunther, Sabina Sieri, María Dolores Chirlaque, Jenny Brändstedt, Giovanna Masala, Hendrik B. Bueno-de-Mesquita, Domenico Palli, María José Sánchez, Inger T. Gram, Jennifer Ose, Ruth C. Travis, Petra H.M. Peeters, Melissa A. Merritt, and Elio Riboli
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,endocrine system diseases ,biology ,business.industry ,Case-control study ,Cancer ,Odds ratio ,medicine.disease ,female genital diseases and pregnancy complications ,European Prospective Investigation into Cancer and Nutrition ,Sex hormone-binding globulin ,Internal medicine ,Ovarian carcinoma ,medicine ,biology.protein ,Prospective cohort study ,Ovarian cancer ,business - Abstract
The role of endogenous androgens and sex hormone-binding globulin (SHBG) in ovarian carcinogenesis is poorly understood. Epithelial invasive ovarian cancer (EOC) is a heterogeneous disease and there are no prospective data on endogenous androgens and EOC risk by tumor characteristics (histology, grade, stage) or the dualistic model of ovarian carcinogenesis (i.e. type I vs. type II, leading to less or more aggressive tumors). We conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort evaluating androgens and SHBG and invasive EOC risk by tumor characteristics. Female participants who provided a blood sample and were not using exogenous hormones at blood donation were eligible (n = 183,257). A total of 565 eligible women developed EOC; two controls (n = 1,097) were matched per case. We used multivariable conditional logistic regression models. We observed no association between androgens, SHBG and EOC overall. A doubling of androstenedione reduced risk of serous carcinomas by 21% (odds ratio (OR)log2 = 0.79, 95% confidence interval [CI] = [0.64-0.97]). Moreover, associations differed for low-grade and high-grade carcinomas, with positive associations for low-grade and inverse associations for high-grade carcinomas (e.g. androstenedione: low grade: ORlog2 = 1.99 [0.98-4.06]; high grade: ORlog2 = 0.75 [0.61-0.93], phet ≤ 0.01), similar associations were observed for type I/II tumors. This is the first prospective study to evaluate androgens, SHBG and EOC risk by tumor characteristics and type I/II status. Our findings support a possible role of androgens in ovarian carcinogenesis. Additional studies exploring this association are needed.
- Published
- 2014
22. Plasma and dietary carotenoids and vitamins A, C and E and risk of colon and rectal cancer in the European Prospective Investigation into Cancer and Nutrition
- Author
-
Aurelio Barricarte, Ingrid Ljuslinder, Salvatore Panico, Max Leenders, Marc J. Gunter, Ingegerd Johansson, Guy Fagerhazzi, Hendrik B. Bueno-de-Mesquita, Domenico Palli, Carla H. van Gils, Marcial Argüelles, Kay-Tee Khaw, José María Huerta, Anne-Claire Vergnaud, Cecilie Kyrø, Mazda Jenab, Anna Androulidaki, Pietro Ferrari, Paul J.M. Hulshof, Paula Jakszyn, Peter D. Siersema, Timothy J. Key, Marie-Christine Boutron-Ruault, Talita Duarte-Salles, Sara Grioni, Rosario Tumino, Heiner Boeing, Nicholas J. Wareham, Petra A. Wark, Carlotta Sacerdote, Nina Roswall, Kathryn E. Bradbury, Anke M. Leufkens, Alina Vrieling, Marije F. Bakker, Fränzel J.B. Van Duijnhoven, Krasimira Aleksandrova, Tilman Kühn, Theron Johnson, Kim Overvad, Eleni Klinaki, Claire Cadeau, Guri Skeie, Antonia Trichopoulou, Esther Molina-Montes, and Elisabete Weiderpass
- Subjects
chemistry.chemical_classification ,Cancer Research ,medicine.medical_specialty ,business.industry ,Colorectal cancer ,Vitamin E ,medicine.medical_treatment ,Retinol ,Cancer ,medicine.disease ,Ascorbic acid ,Lower risk ,Gastroenterology ,European Prospective Investigation into Cancer and Nutrition ,chemistry.chemical_compound ,Endocrinology ,Oncology ,chemistry ,Internal medicine ,medicine ,business ,Carotenoid - Abstract
Carotenoids and vitamins A, C and E are possibly associated with a reduced colorectal cancer (CRC) risk through antioxidative properties. The association of prediagnostic plasma concentrations and dietary consumption of carotenoids and vitamins A, C and E with the risk of colon and rectal cancer was examined in this case-control study, nested within the European Prospective Investigation into Cancer and Nutrition study. Plasma concentrations of carotenoids (α- and β-carotene, canthaxanthin, β-cryptoxanthin, lutein, lycopene, zeaxanthin) and vitamins A (retinol), C and E (α-, β- and γ- and δ-tocopherol) and dietary consumption of β-carotene and vitamins A, C and E were determined in 898 colon cancer cases, 501 rectal cancer cases and 1,399 matched controls. Multivariable conditional logistic regression models were performed to estimate incidence rate ratios (IRR) and corresponding 95% confidence intervals (CIs). An association was observed between higher prediagnostic plasma retinol concentration and a lower risk of colon cancer (IRR for highest quartile = 0.63, 95% CI: 0.46, 0.87, p for trend = 0.01), most notably proximal colon cancer (IRR for highest quartile = 0.46, 95% CI: 0.27, 0.77, p for trend = 0.01). Additionally, inverse associations for dietary β-carotene and dietary vitamins C and E with (distal) colon cancer were observed. Although other associations were suggested, there seems little evidence for a role of these selected compounds in preventing CRC through their antioxidative properties.
- Published
- 2014
23. Dairy products and risk of hepatocellular carcinoma: The European Prospective Investigation into Cancer and Nutrition
- Author
-
Krasimira Aleksandrova, Valeria Pala, Elio Riboli, Emily Sonestedt, Aurelio Barricarte, Kim Overvad, Antonia Trichopoulou, Maria Wennberg, Petra H.M. Peeters, Nicholas J. Wareham, Mazda Jenab, Dimitrios Trichopoulos, Magdalena Stepien, Björn Lindkvist, Ana Fonseca-Nunes, Claire Cadeau, Ingegerd Johansson, Esther Molina-Montes, Inger T. Gram, Ruth C. Travis, Anne Tjønneland, Elisabete Weiderpass, Hendrik B. Bueno-de-Mesquita, Domenico Palli, José Ramón Quirós, Christina Bamia, Carlotta Sacerdote, Pagona Lagiou, Salvatore Panico, Talita Duarte-Salles, Paolo Boffetta, Marie-Christine Boutron-Ruault, Veronika Fedirko, Vincent K. Dik, Rosario Tumino, Tilman Kühn, Konstantinos Tsiotas, Carmen Navarro Sánchez, Jytte Halkjær, Kay-Tee Khaw, Miren Dorronsoro, Antoine Racine, Isabelle Romieu, Elisabeth Trepo, Annekatrin Lukanova, and Anette Hjartåker
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Hazard ratio ,Odds ratio ,medicine.disease ,Gastroenterology ,European Prospective Investigation into Cancer and Nutrition ,Hepatocellular carcinoma ,Internal medicine ,Cohort ,medicine ,Vitamin D and neurology ,business ,Prospective cohort study ,Cohort study - Abstract
Intake of dairy products has been associated with risk of some cancers, but findings are often inconsistent and information on hepatocellular carcinoma (HCC) risk is limited, particularly from prospective settings. The aim of our study was to investigate the association between consumption of total and specific dairy products (milk/cheese/yogurt) and their components (calcium/vitamin D/fats/protein), with first incident HCC (N(cases) = 191) in the European Prospective Investigation into Cancer and Nutrition cohort, including a nested case-control subset (N(cases) = 122) with the assessment of hepatitis B virus/hepatitis C virus infections status, liver damage and circulating insulin-like growth factor (IGF)-I levels. For cohort analyses, multivariable-adjusted Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% confidence intervals (95% CI). For nested case-control analyses, conditional logistic regression was used to calculate odds ratios and 95% CI. A total of 477,206 participants were followed-up for an average of 11 years (person-years follow-up = 5,415,385). In the cohort study, a significant positive HCC risk association was observed for total dairy products (highest vs. lowest tertile, HR = 1.66, 95% CI: 1.13-2.43; p(trend) = 0.012), milk (HR = 1.51, 95% CI: 1.02-2.24; p(trend) = 0.049), and cheese (HR = 1.56, 95% CI: 1.02-2.38; p(trend) = 0.101), but not yogurt (HR = 0.94, 95% CI: 0.65-1.35). Dietary calcium, vitamin D, fat and protein from dairy sources were associated with increased HCC risk, whereas the same nutrients from nondairy sources showed inverse or null associations. In the nested case-control study, similar results were observed among hepatitis-free individuals. Results from this large prospective cohort study suggest that higher consumption of dairy products, particularly milk and cheese, may be associated with increased HCC risk. Validation of these findings in other populations is necessary. Potential biologic mechanisms require further exploration.
- Published
- 2014
24. Prospective seroepidemiologic study on the role of Human Papillomavirus and other infections in cervical carcinogenesis: Evidence from the EPIC cohort
- Author
-
Ruth C. Travis, Maria Hortlund, Françoise Clavel-Chapelon, Petra H.M. Peeters, Tim Waterboer, N. Margall, Annekatrin Lukanova, Rudolf Kaaks, Silvia de Sanjosé, F. Xavier Bosch, Amalia Mattiello, Nicholas J. Wareham, Inger T. Gram, David Lindquist, Christian Munk, Kay-Tee Khaw, Elio Riboli, Aurelio Barricarte, Michael Pawlita, J. Ramón Quirós, Eiliv Lund, Silvia Franceschi, Carlotta Sacerdote, Valeria Pala, Guy Fagherazzi, Xavier Castellsagué, Massimo Tommasino, Marie-Christine Boutron-Ruault, Hendrik B. Bueno-de-Mesquita, Domenico Palli, Kim Overvad, Carlos A. González, Eleni Klinaki, Joakim Dillner, Sabina Rinaldi, Carmen Navarro, Rosario Tumino, Nerea Larrañaga, Ruanne V. Barnabas, María José Sánchez, Anne Tjønneland, Esther Roura, Johanna Ekström, Dimitrios Trichopoulos, Elisabete Weiderpass, Annika Steffen, and Antonia Trichopoulou
- Subjects
Oncology ,Cervical cancer ,Cancer Research ,medicine.medical_specialty ,Chlamydia ,business.industry ,EPIC ,medicine.disease_cause ,medicine.disease ,Serology ,Cervical carcinogenesis ,Internal medicine ,Immunology ,Cohort ,medicine ,Chlamydia trachomatis ,business ,Cohort study - Abstract
To evaluate prospectively the association between serological markers of selected infections, including HPV, and risk of developing cervical cancer (CC) and pre-cancer, we performed a nested case-c ...
- Published
- 2014
25. Smoking as a major risk factor for cervical cancer and pre-cancer: Results from the EPIC cohort
- Author
-
Maria Hortlund, Petra H.M. Peeters, N. Margall, Tim Waterboer, Elio Riboli, Kay-Tee Khaw, Johanna Ekström, Eiliv Lund, Aurelio Barricarte, Annekatrin Lukanova, Carlotta Sacerdote, Massimo Tommasino, M. Luisa Redondo, Dimitrios Trichopoulos, Valeria Pala, María José Tormo, Françoise Clavel-Chapelon, Christian Munk, Rudolf Kaaks, Kim Overvad, Marie-Christine Boutron-Ruault, Nicholas J. Wareham, Ruth C. Travis, Silvia Franceschi, Eleni Klinaki, Noémie Travier, Salvatore Panico, Nerea Larrañaga, Joakim Dillner, Rosario Tumino, Esther Roura, Silvia de Sanjosé, Xavier Castellsagué, Anne Tjønneland, David Lindquist, Michael Pawlita, Guy Fagherazzi, Hendrik B. Bueno-de-Mesquita, Domenico Palli, Sabina Rinaldi, Ruanne V. Barnabas, Elisabete Weiderpass, F. Xavier Bosch, Antonia Trichopoulou, María José Sánchez, Inger T. Gram, and Annika Steffen
- Subjects
Cervical cancer ,Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Cancer ,EPIC ,medicine.disease ,European Prospective Investigation into Cancer and Nutrition ,Internal medicine ,Cohort ,medicine ,Risk factor ,business ,Cohort study - Abstract
A total of 308,036 women were selected from the European Prospective Investigation into Cancer and Nutrition (EPIC) to evaluate the association between tobacco smoking and the risk of cervical intr ...
- Published
- 2014
26. Insulin-like growth factor I and risk of breast cancer by age and hormone receptor status-A prospective study within the EPIC cohort
- Author
-
Petra H.M. Peeters, Domenico Palli, Françoise Clavel-Chapelon, Eiliv Lund, Elio Riboli, Rudolf Kaaks, Anne Andersson, Ruth C. Travis, Marcial Argüelles, Antonia Trichopoulou, Isabelle Romieu, Madlen Schütze, Melissa A. Merritt, Sabina Rinaldi, Kaja Tikk, Pagona Lagiou, Sara Grioni, Theron Johnson, Annekatrin Lukanova, H. Bas Bueno-de-Mesquita, Kim Overvad, Timothy J. Key, Pilar Amiano, Elisabete Weiderpass, Disorn Sookthai, Heiner Boeing, Carla H. van Gils, Kay-Tee Khaw, Malin Sund, Eva Ardanaz, María Dolores Chirlaque, Rosario Tumino, Nicholas J. Wareham, Nina Roswall, Marie-Christine Boutron-Ruault, Genevieve Buckland, Salvatore Panico, Dimitrios Trichopoulos, Marc J. Gunter, Anne Tjønneland, Laure Dossus, Inger T. Gram, María José Sánchez, and Carlotta Sacerdote
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.drug_class ,business.industry ,Case-control study ,Estrogen receptor ,Odds ratio ,medicine.disease ,European Prospective Investigation into Cancer and Nutrition ,Menopause ,Breast cancer ,Estrogen ,Internal medicine ,medicine ,business ,Prospective cohort study - Abstract
Experimental evidence shows cross-talk in mammary cells between estrogen, insulin-like growth factor I (IGF-I) and their respective receptors and possible synergistic effects of estrogen receptor (ER) activation and increased IGF-I signaling with regard to breast tumor development, and epidemiological evidence suggests that circulating IGF-I levels may be related more to the risk of ER-positive than ER-negative breast cancer. Using a case-control study nested within the prospective European EPIC cohort (938 breast cancer cases and 1,394 matched control subjects), we analyzed the relationships of prediagnostic serum IGF-I levels with the risk of estrogen and progesterone receptor-positive and -negative breast tumors. IGF-I levels were positively associated with the risk of ER+ breast tumors overall (pre- and postmenopausal women combined, odds ratio (OR)Q4-Q1 = 1.41 [95% confidence interval (CI) 1.01-1.98] for the highest vs. lowest quartile; OR = 1.17 [95% CI 1.04-1.33] per 1-standard deviation (SD) increase in IGF-I, ptrend = 0.01) and among women who were diagnosed with breast cancer at 50 years or older (ORQ3-Q1 = 1.38 [95% CI 1.01-1.89]; OR = 1.19 [95% CI 1.04-1.36] per 1-SD increase in IGF-I, ptrend = 0.01) but not with receptor-positive disease diagnosed at an earlier age. No statistically significant associations were observed for ER- breast tumors overall and by age at diagnosis. Tests for heterogeneity by receptor status of the tumor were not statistically significant, except for women diagnosed with breast cancer at 50 years or older (phet = 0.03 for ER+/PR+ vs. ER-/PR- disease). Our data add to a global body of evidence indicating that higher circulating IGF-I levels may increase risk specifically of receptor-positive, but not receptor-negative, breast cancer diagnosed at 50 years or older.
- Published
- 2013
27. Adherence to the Mediterranean diet and risk of bladder cancer in the EPIC cohort study
- Author
-
Carlotta Sacerdote, Elisabete Weiderpass, P. H. Peeters, Kim Overvad, Martine M. Ros, Kay-Tee Khaw, Domenico Palli, NJ Wareham, Roy Ehrnström, Johan Malm, Genevieve Buckland, F. Clavel-Chapelon, Kostas Tsiotas, Amalia Mattiello, Dora Romaguera, Jenny Chang-Claude, Rosario Tumino, M-J Sanchez, Anne Tjønneland, Isabelle Romieu, Aurelio Barricarte, Lena Maria Nilsson, Pilar Amiano, Noémie Travier, Eleni Oikonomou, Börje Ljungberg, Guy Fagherazzi, Antonia Trichopoulou, Elio Riboli, M. C. Boutron-Ruault, Rudolf Kaaks, Timothy J. Key, Guri Skeie, J. R. Quirós, Naomi E. Allen, C. A. Gonzalez, Heiner Boeing, Claudia Agnoli, Lambertus A. Kiemeney, M-D Chirlaque, H. B. Bueno-de-Mesquita, Inger T. Gram, and N. Roswall
- Subjects
Gynecology ,Cancer Research ,medicine.medical_specialty ,Bladder cancer ,Mediterranean diet ,Proportional hazards model ,business.industry ,Cancer ,medicine.disease ,European Prospective Investigation into Cancer and Nutrition ,Oncology ,Internal medicine ,Epidemiology ,medicine ,business ,Biomedical sciences ,Cohort study - Abstract
There is growing evidence of the protective role of the Mediterranean diet (MD) on cancer. However, to date no epidemiological study has investigated the influence of the MD on bladder cancer. We evaluated the association between adherence to the MD and risk of urothelial cell bladder cancer (UCC), according to tumor aggressiveness, in the European Prospective Investigation into Cancer and Nutrition (EPIC). The analysis included 477,312 participants, recruited from ten European countries between 1991 and 2000. Information from validated dietary questionnaires was used to develop a relative Mediterranean diet score (rMED), including nine dietary components. Cox regression models were used to assess the effect of the rMED on UCC risk, while adjusting for dietary energy and tobacco smoking of any kind. Stratified analyses were performed by sex, BMI, smoking status, European region and age at diagnosis. During an average follow-up of 11 years, 1,425 participants (70.9% male) were diagnosed with a first primary UCC. There was a negative but non-significant association between a high versus low rMED score and risk of UCC overall (HR: 0.84 [95% CI 0.69, 1.03]) and risk of aggressive (HR: 0.88 [95% CI 0.61, 1.28]) and non-aggressive tumors (HR: 0.78 [95% CI 0.54, 1.14]). Although there was no effect modification in the stratified analyses, there was a significant 34% (p = 0.043) decreased risk of UCC in current smokers with a high rMED score. In EPIC, the MD was not significantly associated with risk of UCC, although we cannot exclude that a MD may reduce risk in current smokers.
- Published
- 2013
28. Dietary flavonoid, lignan and antioxidant capacity and risk of hepatocellular carcinoma in the European prospective investigation into cancer and nutrition study
- Author
-
Carlos González, Annekatrin Lukanova, H. Bas Bueno-de-Mesquita, Elisabete Weiderpass, Rikard Landberg, Calogero Saieva, Eva Ardanaz, Marcial Argüelles, María José Tormo, Antonia Trichopoulou, Christina Bamia, Jytte Halkjær, Talita Duarte-Salles, Esther Molina-Montes, Petra H.M. Peeters, Emily Sonestedt, Mazda Jenab, Raul Zamora-Ros, Elio Riboli, Francesca L. Crowe, Guri Skeie, Guy Fagherazzi, Ute Nöthlings, Claudia Agnoli, Lea Bredsdorff, Ulrika Ericson, Rosario Tumino, Marie-Christine Boutron-Ruault, Verena Katzke, Anna Floegel, Mauro Serafini, Florence Perquier, Kay-Tee Khaw, Kim Overvad, Carlotta Sacerdote, Dagrun Engeset, Veronika Fedirko, Anne Tjønneland, Dimitrios Trichopoulos, Pagona Lagiou, Miren Dorronsoro, Amalia Mattiello, Nicholas J. Wareham, Elisabeth Trepo, Heiner Boeing, and Malin Sund
- Subjects
Cancer Research ,medicine.medical_specialty ,030309 nutrition & dietetics ,Flavonoid ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Statistical significance ,Epidemiology ,medicine ,2. Zero hunger ,chemistry.chemical_classification ,0303 health sciences ,Proportional hazards model ,business.industry ,Hepatitis B ,medicine.disease ,3. Good health ,European Prospective Investigation into Cancer and Nutrition ,Surgery ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Cohort ,business - Abstract
Limited epidemiological evidence suggests a protective role for plant foods rich in flavonoids and antioxidants in hepatocellular cancer (HCC) etiology. Our aim was to prospectively investigate the association between dietary intake of flavonoids, lignans and nonenzymatic antioxidant capacity (NEAC) and HCC risk. Data from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort including 477,206 subjects (29.8% male) recruited from ten Western European countries, was analyzed. Flavonoid, lignan and NEAC intakes were calculated using a compilation of existing food composition databases linked to dietary information from validated dietary questionnaires. Dietary NEAC was based on ferric reducing antioxidant capacity (FRAP) and total radical-trapping antioxidant parameter (TRAP). Hepatitis B/C status was measured in a nested case-control subset. During a mean follow-up of 11-years, 191 incident HCC cases (66.5% men) were identified. Using Cox regression, multivariable adjusted models showed a borderline nonsignificant association of HCC with total flavonoid intake (highest versus lowest tertile, HR = 0.65, 95% CI: 0.40-1.04; p(trend) = 0.065), but not with lignans. Among flavonoid subclasses, flavanols were inversely associated with HCC risk (HR = 0.62, 95% CI: 0.39-0.99; p(trend) = 0.06). Dietary NEAC was inversely associated with HCC (FRAP: HR 0.50, 95% CI: 0.31-0.81; p(trend) = 0.001; TRAP: HR 0.49, 95% CI: 0.31-0.79; p(trend) = 0.002), but statistical significance was lost after exclusion of the first 2 years of follow-up. This study suggests that higher intake of dietary flavanols and antioxidants may be associated with a reduced HCC risk.
- Published
- 2013
29. Polymorphisms in theXRCC1gene modify survival of bladder cancer patients treated with chemotherapy
- Author
-
Andrea Zitella, Alessandra Allione, Simonetta Guarrera, Fulvio Ricceri, Giuseppe Matullo, Andrea Bosio, Alessia Russo, Giuseppina Cucchiarale, Barbara Pardini, Paolo Gontero, Dario Fontana, Xifeng Wu, Angeline S. Andrew, Yuanqing Ye, Rossana Critelli, Paolo Destefanis, Luigi Rolle, Giovanni Casetta, Paolo Vineis, Silvia Polidoro, Carlotta Sacerdote, and Lambertus A. Kiemeney
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Bladder cancer ,DNA repair ,Hazard ratio ,Cancer ,Single-nucleotide polymorphism ,Biology ,medicine.disease ,XRCC1 ,Internal medicine ,Genotype ,Cancer research ,medicine ,XRCC1 Gene - Abstract
Survival of bladder cancer patients depends on several factors including disease stage and grade at diagnosis, age, health status of the patient and the applied treatment. Several studies investigated the role of DNA repair genetic variants in cancer susceptibility, but only few studies investigated their role in survival and response to chemotherapy for bladder cancer. We genotyped 28 single nucleotide polymorphisms (SNP) in DNA repair genes in 456 bladder cancer patients, reconstructed haplotypes and calculated a score for combinations of the SNPs. We estimated Hazard Ratios (adjHR) for time to death. Among patients treated with chemotherapy, variant alleles of five SNPs in the XRCC1 gene conferred better survival (rs915927 adjHR 0.55 (95%CI 0.32–0.94); rs76507 adjHR 0.48 (95%CI 0.27–0.84); rs2854501 adjHR 0.25 (95%CI 0.12–0.52); rs2854509 adjHR 0.21 (95%CI 0.09–0.46); rs3213255 adjHR 0.46 (95%CI 0.26–0.80). In this group of patients, an increasing number of variant alleles in a XRCC1 gene score were associated with a better survival (26% decrease of risk of death for each additional variant allele in XRCC1). By functional analyses we demonstrated that the previous XRCC1 SNPs confer lower DNA repair capacity. This may support the hypothesis that survival in these patients may be modulated by the different DNA repair capacity determined by genetic variants. Chemotherapy treated cancer patients bearing an increasing number of “risky” alleles in XRCC1 gene had a better survival, suggesting that a proficient DNA repair may result in resistance to therapy and shorter survival. This finding may have clinical implications for the choice of therapy.
- Published
- 2013
30. Plasma 25-hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: A nested case-control study
- Author
-
Jakob Linseisen, Elio Riboli, Christina Bamia, Françoise Clavel-Chapelon, Kay-Tee Khaw, Piia Piret Eomois, Valentina Gallo, Ruth C. Travis, Nicholas J. Wareham, Antonia Trichopoulou, Amalia Mattiello, Pagona Lagiou, Neil Murphy, María Dolores Chirlaque, Elisabete Weiderpass, Heiner Boeing, Magritt Brustad, Aurelio Barricarte, Julie A. Schmidt, Susen Becker, Malin Sund, Guri Skeie, Carla H. van Gils, Anne Andersson, Rosario Tumino, Marina Kvaskoff, Fränzel J.B. Van Duijnhoven, Anja Olsen, Virginia Menéndez, Kim Overvad, Carlotta Sacerdote, Rudolf Kaaks, Anne Tjønneland, Laure Dossus, Sabina Rinaldi, Giovanna Masala, María José Sánchez, Genevieve Buckland, Tilman Kühn, Marije F. Bakker, Vittorio Krogh, Isabelle Romieu, Annekatrin Lukanova, H. Bas Bueno-de-Mesquita, Jenny Chang-Claude, and Brian Buijsse
- Subjects
Oncology ,0303 health sciences ,Cancer Research ,medicine.medical_specialty ,Inverse Association ,business.industry ,medicine.medical_treatment ,Estrogen receptor ,Hormone replacement therapy (menopause) ,medicine.disease ,3. Good health ,European Prospective Investigation into Cancer and Nutrition ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,030220 oncology & carcinogenesis ,Internal medicine ,Nested case-control study ,medicine ,Vitamin D and neurology ,business ,Prospective cohort study ,030304 developmental biology - Abstract
Experimental evidence suggests that vitamin D might play a role in the development of breast cancer. Although the results of case-control studies indicate that circulating 25-hydroxyvitamin D [25(OH)D] is inversely associated with the risk of breast cancer, the results of prospective studies are inconsistent. A case-control study embedded in the European Prospective Investigation into Cancer and Nutrition (EPIC) was carried out comprising 1,391 incident breast cancer cases and 1,391 controls. Multivariable conditional logistic regression models did not reveal a significant overall association between season-standardized 25(OH)D levels and the risk of breast cancer (ORQ4-Q1 [95% CI]: 1.07 [0.85-1.36], ptrend = 0.67). Moreover, 25(OH)D levels were not related to the risks of estrogen receptor positive tumors (ORQ4-Q1 [95% CI]: 0.97 [0.67-1.38], ptrend = 0.90) and estrogen receptor negative tumors (ORQ4-Q1 [95% CI]: 0.97 [0.66-1.42], ptrend = 0.98). In hormone replacement therapy (HRT) users, 25(OH)D was significantly inversely associated with incident breast cancer (ORlog2 [95% CI]: 0.62 [0.42-0.90], p = 0.01), whereas no significant association was found in HRT nonusers (ORlog2 [95% CI]: 1.14 [0.80-1.62], p = 0.48). Further, a nonsignificant inverse association was found in women with body mass indices (BMI) < 25 kg/m(2) (ORlog2 [95% CI]: 0.83 [0.67-1.03], p = 0.09), as opposed to a borderline significant positive association in women with BMI ≥ 25 kg/m(2) (ORlog2 [95% CI]: 1.30 [1.0-1.69], p = 0.05). Overall, prediagnostic levels of circulating 25(OH)D were not related to the risk of breast cancer in the EPIC study. This result is in line with findings in the majority of prospective studies and does not support a role of vitamin D in the development of breast cancer.
- Published
- 2013
31. Italian mediterranean index and risk of colorectal cancer in the Italian section of the EPIC cohort
- Author
-
Sabina Sieri, Rosario Tumino, Valeria Pala, Claudia Agnoli, Sara Grioni, Domenico Palli, Franco Berrino, Salvatore Panico, Paolo Vineis, Amalia Mattiello, Maria Concetta Giurdanella, Giovanna Masala, Carlotta Sacerdote, Vittorio Krogh, Agnoli, C, Grioni, S, Sieri, S, Palli, D, Masala, G, Sacerdote, C, Vineis, P, Tumino, R, Giurdanella, Mc, Pala, V, Berrino, F, Mattiello, A, Panico, Salvatore, and Krogh, V.
- Subjects
Adult ,Male ,Risk ,Oncology ,Cancer Research ,medicine.medical_specialty ,Mediterranean diet ,Colorectal cancer ,Diet, Mediterranean ,Diet Surveys ,Cohort Studies ,Surveys and Questionnaires ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Proportional Hazards Models ,Proportional hazards model ,business.industry ,Hazard ratio ,Cancer ,Middle Aged ,medicine.disease ,Italy ,Cohort ,Female ,Colorectal Neoplasms ,business ,Follow-Up Studies ,Cohort study - Abstract
Colorectal cancer is among the commonest cancers worldwide. Dietary factors have been linked to colorectal cancer risk, however, few studies have evaluated the relationship between a priori dietary patterns and colorectal cancer risk. We evaluated the effect of adherence to a Mediterranean dietary pattern, as measured by the Italian Mediterranean Index, on the risk of colorectal cancer in the 45,275 participants of the Italian section of the EPIC study who completed a dietary questionnaire. Hazard ratios (HRs) with 95% confidence intervals (CIs) for colorectal cancer in relation to categories of Italian Mediterranean Index score were estimated by multivariate Cox models adjusted for known risk factors, on the whole cohort, on men and women and according to cancer subsite. During a mean follow-up of 11.28 years, 435 colorectal cancer cases were identified. The Italian Mediterranean Index was inversely associated with colorectal cancer risk (HR: 0.50; 95% CI: 0.35-0.71 for the highest category compared to the lowest, P-trend: 0.043). Results did not differ by sex. Highest Italian Mediterranean Index score was also significantly associated with reduced risks of any colon cancer (HR: 0.54, 95% CI: 0.36-0.81), distal colon cancer (HR: 0.44, 95% CI: 0.26-0.75) and rectal cancer (HR: 0.41, 95% CI: 0.20-0.81), but not of proximal colon cancer. These findings suggest that adherence to a Mediterranean diet (as measured by the Italian Mediterranean Index) protects against colorectal cancer in general but not against cancer developing in the proximal colon.
- Published
- 2012
32. Macronutrient intake and risk of urothelial cell carcinoma in the European prospective investigation into cancer and nutrition
- Author
-
Christine L. Parr, Lambertus A. Kiemeney, Kim Overvad, Göran Hallmans, Martine M. Ros, José Ramón Quirós, Guy Fagherrazzi, Tina Karapetyan, Isabelle Romieu, Ulrika Ericson, Marc J. Gunter, Inger T. Gram, Roy Ehrnström, Paul N. Appleby, Nina Roswall, H. B. Bueno-de-Mesquita, Domenico Palli, Birgit Teucher, Börje Ljungberg, Jenny Chang-Claude, Carlotta Sacerdote, Petra H.M. Peeters, Nicholas J. Wareham, Heiner Boeing, Kay-Tee Khaw, Eva Ardanaz, Elio Riboli, Françoise Clavel-Chapelon, María Dolores Chirlaque, Miren Dorronsoro, Rosario Tumino, Naomi E. Allen, Vardis Dilis, Antonia Trichopoulou, Timothy J. Key, Sabina Sieri, Esther Molina-Montes, Anne Tjønneland, Steffen Weikert, Paula Jakszyn, Marie-Christine Boutron-Ruault, Salvatore Panico, Allen, Ne, Appleby, Pn, Key, Tj, Bueno de Mesquita, Hb, Ros, Mm, Kiemeney, La, Tj?nneland, A, Roswall, N, Overvad, K, Weikert, S, Boeing, H, Chang Claude, J, Teucher, B, Panico, Salvatore, Sacerdote, C, Tumino, R, Palli, D, Sieri, S, Peeters, P, Quir?s, Jr, Jakszyn, P, Molina Montes, E, Chirlaque, Md, Ardanaz, E, Dorronsoro, M, Khaw, Kt, Wareham, N, Ljungberg, B, Hallmans, G, Ehrnstr?m, R, Ericson, U, Gram, It, Parr, Cl, Trichopoulou, A, Karapetyan, T, Dilis, V, Clavel Chapelon, F, Boutron Ruault, Mc, Fagherrazzi, G, Romieu, I, Gunter, Mj, and Riboli, E.
- Subjects
Adult ,Dietary Fiber ,Male ,Cancer Research ,medicine.medical_specialty ,Meat ,Urinary Bladder ,Nutritional Status ,Physiology ,Aetiology, screening and detection [ONCOL 5] ,Lower risk ,Plant Proteins, Dietary ,Risk Assessment ,Body Mass Index ,Risk Factors ,Surveys and Questionnaires ,Internal medicine ,Dietary Carbohydrates ,medicine ,Carcinoma ,Humans ,Prospective Studies ,Prospective cohort study ,Aged ,Molecular epidemiology Aetiology, screening and detection [NCEBP 1] ,Aged, 80 and over ,Bladder cancer ,business.industry ,Smoking ,Feeding Behavior ,Middle Aged ,medicine.disease ,Dietary Fats ,Diet ,European Prospective Investigation into Cancer and Nutrition ,Calcium, Dietary ,Europe ,Endocrinology ,Urinary Bladder Neoplasms ,Oncology ,Plant protein ,Female ,Dietary Proteins ,Risk assessment ,business ,Body mass index - Abstract
Item does not contain fulltext Previous studies have suggested that dietary factors may be important in the development of bladder cancer. We examined macronutrient intake in relation to risk of urothelial cell carcinoma among 469,339 men and women in the European Prospective Investigation into Cancer and Nutrition. Associations were examined using Cox regression, stratified by sex, age at recruitment and centre and further adjusted for smoking status and duration, body mass index and total energy intake. After an average of 11.3 years of follow-up, 1,416 new cases of urothelial cell carcinoma were identified. After allowing for measurement error, a 3% increase in the consumption of energy intake from animal protein was associated with a 15% higher risk (95% confidence interval [CI]: 3-30%; p(trend) = 0.01) and a 2% increase in energy from plant protein intake was associated with a 23% lower risk (95% CI: 36-7%, p(trend) = 0.006). Dietary intake of fat, carbohydrate, fibre or calcium was not associated with risk. These findings suggest that animal and/or plant protein may affect the risk of urothelial cell carcinoma, and examination of these associations in other studies is needed.
- Published
- 2012
33. Olive oil intake and breast cancer risk in the Mediterranean countries of the European Prospective Investigation into Cancer and Nutrition study
- Author
-
Antonio Agudo, J. Ramón Quirós, Eva Ardanaz, Christiana A. Demetriou, Miren Dorronsoro, Amalia Mattiello, Antonia Trichopoulou, Noémie Travier, Carmen Navarro, José María Huerta, Carlotta Sacerdote, Pagona Lagiou, Sara Grioni, Giovanna Masala, Silvia Polidoro, Claudia Agnoli, María José Pérez, Androniki Naska, Ana Fonseca-Nunes, Esther Molina, Dimitrios Trichopoulos, Genevieve Buckland, Salvatore Panico, María Dolores Chirlaque, Pilar Amiano, Rosario Tumino, Conchi Moreno-Iribas, Domenico Palli, Maria Concetta Giurdanella, Carlos González, Buckland, G, Travier, N, Agudo, A, Fonseca Nunes, A, Navarro, C, Lagiou, P, Demetriou, C, Amiano, P, Dorronsoro, M, Chirlaque, Md, Huerta, Jm, Molina, E, P?rez, Mj, Ardanaz, E, Moreno Iribas, C, Quir?s, Jr, Naska, A, Trichopoulos, D, Giurdanella, Mc, Tumino, R, Agnoli, C, Grioni, S, Panico, Salvatore, Mattiello, A, Masala, G, Sacerdote, C, Polidoro, S, Palli, D, Trichopoulou, A, and Gonz?lez, Ca
- Subjects
Risk ,Cancer Research ,medicine.medical_specialty ,medicine.drug_class ,Breast Neoplasms ,Cohort Studies ,Breast cancer ,Epidemiology ,Humans ,Plant Oils ,Medicine ,Prospective cohort study ,Olive Oil ,Gynecology ,Mediterranean Region ,business.industry ,medicine.disease ,Diet ,European Prospective Investigation into Cancer and Nutrition ,Postmenopause ,Receptors, Estrogen ,Oncology ,Hormone receptor ,Estrogen ,Female ,Receptors, Progesterone ,business ,Demography ,Olive oil ,Cohort study - Abstract
Although there is some evidence suggesting that olive oil could reduce breast cancer (BC) risk, the epidemiological data are still relatively limited, not entirely consistent and mainly based on case-control studies. Therefore, we prospectively assessed the association between olive oil and BC risk in postmenopausal women from the Mediterranean cohorts within the European Prospective Investigation into Cancer and Nutrition. The analysis included 62,284 postmenopausal women recruited from Spain, Italy and Greece who had complete dietary data (collected from validated country-specific dietary questionnaires). The risk of BC (overall and by hormone receptor subtypes) was assessed using hazards ratios (HRs) obtained from Cox proportional hazards regression, while adjusting for known BC risk factors. After a mean follow-up of 9 years, 1,256 women were diagnosed with a primary incident invasive BC. The multivariate HRs for BC risk by olive oil intake (highest vs. lowest tertile of g/day/2,000 kcal) were 1.07 (95% CI = 0.91-1.25) in the adjusted model, 1.06 (95% CI = 0.91-1.24) in the model additionally adjusted for reproductive-related factors and 1.10 (95% CI = 0.92-1.31) for the model additionally adjusted for dietary factors. There was no association between olive oil and risk of estrogen or progesterone receptor-positive tumors, but a suggestion of a negative association with estrogens and progesterone receptor-negative tumors. The results from our prospective study showed that olive oil consumption during adult life was not associated with the risk of BC. However, larger prospective studies are still needed to explore possible differences related to hormone receptor status.
- Published
- 2012
34. Plasma cotinine levels and pancreatic cancer in the EPIC cohort study
- Author
-
Øivind Midttun, Per Magne Ueland, Dominique S. Michaud, H. Bas Bueno-de-Mesquita, Jytte Halkjaer, Anne Tjønneland, Elio Riboli, Paolo Vineis, Eiliv Lund, Esther Molina-Montes, Shu Chun Chuang, Kay-Tee Khaw, Domenico Palli, Christina C. Dahm, Christina Bamia, Marie-Christine Boutron-Ruault, Stein Emil Vollset, Rudolf Kaaks, Rosario Tumino, Amalia Mattiello, Nicholas J. Wareham, Carlotta Sacerdote, Antonia Trichopoulou, Mazda Jenab, Eric J. Duell, Federico Canzian, Björn Lindkvist, Aurelio Barricarte, Nerea Larrañaga, Cornelia Weikert, Weimin Ye, Petra H.M. Peeters, Max Leenders, Fränzel J.B. Van Duijnhoven, Francesca L. Crowe, Laudina Rodríguez, Wei W. Xun, Carla H. van Gils, Naomi E. Allen, Dorthe Johansen, Valeria Pala, Kim Overvad, José María Huerta Castaño, Françoise Clavel-Chapelon, Androniki Naska, María José Pérez, Heiner Boeing, and Malin Sund
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Population ,Gastroenterology ,Mass Spectrometry ,Cohort Studies ,chemistry.chemical_compound ,Pancreatic cancer ,Internal medicine ,medicine ,Humans ,Risk factor ,Cotinine ,education ,Gynecology ,education.field_of_study ,business.industry ,Smoking ,Cancer ,Odds ratio ,medicine.disease ,European Prospective Investigation into Cancer and Nutrition ,Pancreatic Neoplasms ,Human Reproduction [NCEBP 12] ,Logistic Models ,Oncology ,chemistry ,Case-Control Studies ,Female ,business ,Chromatography, Liquid ,Cohort study - Abstract
Item does not contain fulltext Smoking is an established risk factor for pancreatic cancer, previously investigated by the means of questionnaires. Using cotinine as a biomarker for tobacco exposure allows more accurate quantitative analyses to be performed. This study on pancreatic cancer, nested within the European Prospective Investigation into Cancer and Nutrition (EPIC cohort), included 146 cases and 146 matched controls. Using liquid chromatography-mass spectrometry, plasma cotinine levels were analyzed on average 8.0 years before cancer onset (5-95% range: 2.8-12.0 years). The relation between plasma cotinine levels and pancreatic cancer was analyzed with conditional logistic regression for different levels of cotinine in a population of never and current smokers. This was also done for the self-reported number of smoked cigarettes per day at baseline. Every increase of 350 nmol/L of plasma cotinine was found to significantly elevate risk of pancreatic cancer [odds ratio (OR): 1.33, 95% confidence interval (CI): 1.11-1.60]. People with a cotinine level over 1187.8 nmol/L, a level comparable to smoking 17 cigarettes per day, have an elevated risk of pancreatic cancer, compared to people with cotinine levels below 55 nmol/L (OR: 3.66, 95% CI: 1.44-9.26). The results for self-reported smoking at baseline also show an increased risk of pancreatic cancer from cigarette smoking based on questionnaire information. People who smoke more than 30 cigarettes per day showed the highest risk compared to never smokers (OR: 4.15, 95% CI: 1.02-16.42). This study is the first to show that plasma cotinine levels are strongly related to pancreatic cancer.
- Published
- 2011
35. Biologic markers of sun exposure and melanoma risk in women: Pooled case-control analysis
- Author
-
Elizabeth A. Holly, Adèle C. Green, Thomas M. Mack, Roberto Zanetti, Stefano Rosso, Julia A. Newton Bishop, Catherine M. Olsen, Michael S. Zens, Therese A. Stukel, Richard P. Gallagher, C. D'Arcy J. Holman, David C. Whiteman, Margaret R. Karagas, J. Mark Elwood, Marianne Berwick, Anne Østerlind, Rona M. MacKie, Connie Kirkpatrick, Veronique Bataille, Anthony J. Swerdlow, Yu-Mei Chang, Bruce K. Armstrong, and Carlotta Sacerdote
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Skin Neoplasms ,Adolescent ,Sunburn ,Article ,visual_art.visual_artist ,Sunbathing ,medicine ,Humans ,Nevus ,Risk factor ,skin and connective tissue diseases ,Melanoma ,Aged ,Aged, 80 and over ,Biologic marker ,business.industry ,Keratosis ,Odds ratio ,Middle Aged ,medicine.disease ,Dermatology ,Solar keratosis ,Oncology ,Case-Control Studies ,visual_art ,Relative risk ,Sunlight ,Female ,business ,Biomarkers - Abstract
A model has been proposed whereby melanomas arise through two distinct pathways dependent on the relative influence of host susceptibility and sun exposure. Such pathways may explain site-specific patterns of melanoma occurrence. To explore this model, we investigated the relationship between melanoma risk and general markers of acute (recalled sunburns) and chronic (prevalent solar keratoses) sun exposure, stratified by anatomic site and host phenotype. Our working hypothesis was that head and neck melanomas have stronger associations with solar keratoses and weaker associations with sunburn than trunk melanomas. We conducted a collaborative analysis using original data from women subjects of 11 case-control studies of melanoma (2,575 cases, 3,241 controls). We adjusted for potential confounding effects of sunlamp use and sunbathing. The magnitude of sunburn associations did not differ significantly by melanoma site, nevus count or histologic subtype of melanoma. Across all sites, relative risk of melanoma increased with an increasing number of reported lifetime "painful" sunburns, lifetime "severe" sunburns and "severe" sunburns in youth (p(trend) < 0.001), with pooled odds ratios (pORs) for the highest category of sunburns versus no sunburns of 3.22 [95% confidence interval (CI) 2.04-5.09] for lifetime "painful" sunburns, 2.10 (95%CI 1.30-3.38) for lifetime "severe" sunburns and 2.43 (95%CI 1.61-3.65) for "severe" sunburns in youth. Solar keratoses strongly increased the risk of head and neck melanoma (pOR 4.91, 95%CI 2.10-11.46), but data were insufficient to assess risk for other sites. Reported sunburn is strongly associated with melanoma on all major body sites.
- Published
- 2010
36. Risk of endometrial cancer in relationship to cigarette smoking: Results from the EPIC study
- Author
-
Göran Hallmans, Eva Lundin, Amalia Mattiello, Kim Overvad, Sabina Rinaldi, Jakob Linseisen, José Ramón Quirós, Heiner Boeing, Naomi E. Allen, H. Bas Bueno-de-Mesquita, Hendriek C. Boshuizen, Anne E. Cust, Estelle Gauthier, Mustafa Al-Zoughool, Travezea Chryssa, Rosario Tumino, Franco Berrino, Inger T. Gram, Elio Riboli, Antonio Agudo, Marie-Christine Boutron-Ruault, Mandy Schulz, Tonje Braaten, Kay-Tee Khaw, Eiliv Lund, Sheila Bingham, María Dolores Chirlaque, Petra H.M. Peeters, Carlotta Sacerdote, Anne Tjønneland, Timothy J. Key, Nerea Larrañaga, Antonia Trichopoulou, Göran Berglund, Eva Ardanaz, Anja Olsen, Laure Dossus, Jonas Manjer, Rudolf Kaaks, Françoise Clavel-Chapelon, Dimitrios Trichopoulos, Mazda Jenab, Domenico Palli, Jenny Chang-Claude, and University of Groningen
- Subjects
Adult ,Oncology ,Cancer Research ,medicine.medical_specialty ,Time Factors ,prospective cohort ,smoking ,REPLACEMENT THERAPY ,Cigarette smoking ,Risk Factors ,Surveys and Questionnaires ,Internal medicine ,SEX-STEROID HORMONES ,Epidemiology ,Odds Ratio ,medicine ,Humans ,EPIDEMIOLOGY ,COHORT ,ddc:610 ,Prospective Studies ,Risk factor ,Prospective cohort study ,Aged ,Gynecology ,Models, Statistical ,HEALTHY WOMEN ,business.industry ,Endometrial cancer ,Age Factors ,Cancer ,Middle Aged ,medicine.disease ,Endometrial Neoplasms ,IGF-I ,Europe ,Postmenopause ,PHYSICAL-ACTIVITY ,Premenopause ,POSTMENOPAUSAL WOMEN ,endometrial cancer ,Cohort ,Female ,NUTRITION ,WEIGHT ,business ,Cohort study - Abstract
Current epidemiologic evidence indicates that cigarette smoking reduces the risk of endometrial cancer. We examined data from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort to analyze further aspects of the smoking-endometrial cancer relationship, such as possible modifying effects of menopausal status, HRT use, BMI and parity. In a total of 249,986 women with smoking exposure and menopausal status information, 619 incident endometrial cancer cases were identified during 1.56 million person-years of follow-up. Among postmenopausal women, the hazard ratio (HR) for current smokers versus never smokers was 0.70 (95% CI = 0.53-0.93), while it was 1.75 (95% CI = 1.13-2.70) among premenopausal women at recruitment. After adjustment for risk factors, the HR for postmenopausal women was slightly attenuated to 0.78 (95% CI = 0.59-1.03). No heterogeneity of effect was observed with HRT use or BMI. Among premenopausal women, current smokers of more than 15 cigarettes per day or who smoked for 30 years or more at the time of recruitment had a more than 2-fold increased risk of endometrial cancer compared to never smokers (HR = 2.54; 95% CI = 1.47-4.38 and HR = 2.23; 95% CI = 1.04-4.77, respectively). Past smoking was not associated with endometrial cancer risk, either among pre- or post-menopausal women. In this prospective study, we observed an increased risk of endometrial cancer with cigarette smoking in premenopausal women. The reduction of endometrial cancer risk observed among postmenopausal women does not have direct public health relevance since cigarette smoking is the main known risk factor for cancer. (c) 2007 Wiley-Liss, Inc.
- Published
- 2007
37. Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses
- Author
-
Fatemeh Saberi, Hosnijeh, Lutzen, Portengen, Florentin, Späth, Ingvar A, Bergdahl, Beatrice, Melin, Amalia, Mattiello, Giovanna, Masala, Carlotta, Sacerdote, Alessio, Naccarati, Vittorio, Krogh, Rosario, Tumino, Marc, Chadeau-Hyam, Paolo, Vineis, and Roel, Vermeulen
- Subjects
Male ,Risk ,Lymphoma, B-Cell ,Case-Control Studies ,Odds Ratio ,Humans ,Ki-1 Antigen ,Female ,Prospective Studies ,Middle Aged ,Lymphocyte Activation ,Biomarkers ,Tumor Necrosis Factor Receptor Superfamily, Member 7 - Abstract
Prediagnostic serum/plasma concentrations of B-cell activation markers have been associated with future risk of B-cell lymphomas (BCL) in HIV-infected patients and in the general population. Current evidence for the general population is however limited and relies on relatively small numbers of observations, especially for specific histologies. We carried out a nested case-control study, including 218 BCL and 218 matched controls, within two prospective cohorts, to investigate the association between plasma levels of soluble (s)CD27 and sCD30 and future risk of BCL, and main histologic subtypes separately. To expand the evidence further, we performed meta-analyses of the published data on these associations from prospective studies among the general population. Our study revealed a significant relationship between sCD30 concentration and BCL risk (OR = 0.86, 1.53, 1.76, for the 2nd-4th quartiles respectively, p trend = 0.01). Similar increased risks were observed for diffuse large B-cell lymphoma and follicular lymphoma. Analyses of sCD27 blood concentrations did not show significant associations with BCL, (OR = 0.90, 1.26, 1.65 for the 2nd-4th quartiles, respectively, p trend = 0.17), but significant associations were observed for chronic lymphocytic leukaemia and for the group of "other BCL" subtypes. Our findings involving sCD30 were confirmed within our meta-analyses of five prospective cohorts, while results were more heterogeneous for sCD27 with the exception of CLL which was found consistently in all studies. Data to date suggest that chronic B-cell stimulation might be an important mechanism involved in B-cell lymphomagenesis both in HIV-infected and in the general population.
- Published
- 2015
38. Body size and breast cancer risk: Findings from the European prospective investigation into cancer and nutrition (EPIC)
- Author
-
Carla H. van Gils, Kim Overvad, Rosario Tumino, Petra H.M. Peeters, Janne Bigaard, Carlotta Sacerdote, Elio Riboli, Gillian K Reeves, Bertrand Tehard, Heiner Boeing, Anja Olsen, Kurt Hoffmann, Franco Berrino, Eva Ardanaz, Pilar Amiano, Elisabet Wirfält, Salvatore Panico, Françoise Clavel-Chapelon, María J. Tormo, Göran Hallmans, Kay-Tee Khaw, Guillem Pera, José Ramón Quirós, Carmen Martinez, Domenico Palli, H. Bas Bueno-de-Mesquita, Göran Berglund, Teresa Norat, Petra H. Lahmann, Timothy J. Key, George D. Economou, Vittorio Krogh, Dimitrios Trichopoulos, Anne Tjønneland, George Bellos, Sheila Bingham, Gabriele Nagel, Carine Biessy, Naomi E. Allen, Rudolf Kaaks, and Eiliv Lund
- Subjects
Cancer Research ,medicine.medical_specialty ,Waist ,Obstetrics ,business.industry ,medicine.medical_treatment ,Absolute risk reduction ,Cancer ,Hormone replacement therapy (menopause) ,medicine.disease ,European Prospective Investigation into Cancer and Nutrition ,Breast cancer ,Endocrinology ,Oncology ,Internal medicine ,medicine ,Risk factor ,business ,Body mass index - Abstract
The evidence for anthropometric factors influencing breast cancer risk is accumulating, but uncertainties remain concerning the role of fat distribution and potential effect modifiers. We used data from 73,542 premenopausal and 103,344 postmenopausal women from 9 European countries, taking part in the EPIC study. RRs from Cox regression models were calculated, using measured height, weight, BMI and waist and hip circumferences; categorized by cohort-wide quintiles; and expressed as continuous variables, adjusted for study center, age and other risk factors. During 4.7 years of follow-up, 1,879 incident invasive breast cancers were identified. In postmenopausal women, current HRT modified the body size-breast cancer association. Among nonusers, weight, BMI and hip circumference were positively associated with breast cancer risk (all ptrend 30) had a 31% excess risk compared to women with BMI < 25. Among HRT users, body measures were inversely but nonsignificantly associated with breast cancer. Excess breast cancer risk with HRT was particularly evident among lean women. Pooled RRs per height increment of 5 cm were 1.05 (95% CI 1.00-1.16) in premenopausal and 1.10 (95% CI 1.05-1.16) in postmenopausal women. Among premenopausal women, hip circumference was the only other measure significantly related to breast cancer (ptrend = 0.03), after accounting for BMI. In postmenopausal women not taking exogenous hormones, general obesity is a significant predictor of breast cancer, while abdominal fat assessed as waist-hip ratio or waist circumference was not related to excess risk when adjusted for BMI. Among premenopausal women, weight and BMI showed nonsignificant inverse associations with breast cancer.
- Published
- 2004
39. Anthropometric measures and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition
- Author
-
Petra H.M. Peeters, Annekatrin Lukanova, Domenico Palli, María José Tormo, H. Bas Bueno-de-Mesquita, Tobias Pischon, Rudolf Kaaks, Teresa Norat, Françoise Clavel-Chapelon, Elio Riboli, Naomi E. Allen, Paula Jakszyn, Heiner Boeing, Larraitz Arriola, Androniki Naska, Elizabeth A Spencer, Jytte Halkjær, Marianne Tang Severinsen, Anne M. May, Kay-Tee Khaw, Pagona Lagiou, Karin Jirström, Kim Overvad, Mandy Schulz, Sheila Bingham, Nathalie Chabbert-Buffet, Nadia Slimani, Sabina Rinaldi, Antonia Trichopoulou, Anne Tjønneland, Carlotta Sacerdote, Christine M. Friedenreich, Anne E. Cust, Eva Ardanaz, Dominique S. Michaud, Laure Dossus, Eva Lundin, Jonas Manjer, Maria Luisa Redondo, María José Sánchez, Veronique Chajes, Amalia Mattiello, Rosario Tumino, Petra H. Lahmann, Agnès Fournier, N. Charlotte Onland-Moret, and Sara Grioni
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Nutritional Status ,Risk Assessment ,Body Mass Index ,03 medical and health sciences ,0302 clinical medicine ,Waist–hip ratio ,Risk Factors ,medicine ,Odds Ratio ,Humans ,030212 general & internal medicine ,Obesity ,Prospective Studies ,Risk factor ,Prospective cohort study ,Aged ,Proportional Hazards Models ,2. Zero hunger ,Gynecology ,Ovarian Neoplasms ,Anthropometry ,Obstetrics ,business.industry ,Waist-Hip Ratio ,Hazard ratio ,Carcinoma ,Cancer ,Odds ratio ,Middle Aged ,medicine.disease ,3. Good health ,European Prospective Investigation into Cancer and Nutrition ,Europe ,Oncology ,030220 oncology & carcinogenesis ,Obesity, Abdominal ,Multivariate Analysis ,Linear Models ,Female ,Menopause ,Waist Circumference ,business ,Body mass index - Abstract
Udgivelsesdato: 2010 We examined the associations of measured anthropometric factors, including general and central adiposity and height, with ovarian cancer risk. We also investigated these associations by menopausal status and for specific histological subtypes. Among 226,798 women in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, there were 611 incident cases of primary, malignant, epithelial ovarian cancer diagnosed during a mean 8.9 years of follow-up. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), adjusted for potential confounders. Compared to women with body mass index (BMI) < 25 kg/m(2), obesity (BMI >/= 30 kg/m(2)) was associated with excess ovarian cancer risk for all women combined (HR = 1.33, 95% CI = 1.05-1.68; p(trend) = 0.02) and postmenopausal women (HR = 1.59, 95% CI = 1.20-2.10; p(trend) = 0.001), but the association was weaker for premenopausal women (HR = 1.16, 95% CI = 0.65-2.06; p(trend) = 0.65). Neither height or weight gain, nor BMI-adjusted measures of fat distribution assessed by waist circumference, waist-hip ratio (WHR) or hip circumference were associated with overall risk. WHR was related to increased risk of mucinous tumors (BMI-adjusted HR per 0.05 unit increment = 1.17, 95% CI = 1.00-1.38). For all women combined, no other significant associations with risk were observed for specific histological subtypes. This large, prospective study provides evidence that obesity is an important modifiable risk factor for epithelial ovarian cancer, particularly among postmenopausal women.
- Published
- 2009
40. Erratum
- Author
-
Kim Overvad, Carmen Martinez, Marie-Christine Boutron-Ruault, Marga C. Ocké, Miren Dorronsoro, Françoise Clavel-Chapelon, Jonas Manjer, Carlos González, Nadia Slimani, Pietro Ferrari, Antonio Agudo, Majken K. Jensen, Salvatore Panico, Mazda Jenab, Michelle Mendez, Rosario Tumino, Göran Berglund, Domenico Palli, Jakob Linseisen, José Ramón Quirós, Timothy J. Key, Mattijs E. Numans, Heiner Boeing, Elio Riboli, Eiliv Lund, H. Bas Bueno-de-Mesquita, Carlotta Sacerdote, Rudolf Kaaks, Sheila Bingham, Antonia Trichopoulou, Fátima Carneiro, Franco Berrino, Guillem Pera, Aurelio Barricarte, Petra H.M. Peeters, Anja Olsen, María J. Tormo, Naomi E. Allen, Roger Stenling, Ingegerd Johansson, and Anne Tjønneland
- Subjects
Oncology ,Cereal fiber ,Cancer Research ,medicine.medical_specialty ,business.industry ,Internal medicine ,medicine ,Cancer ,EPIC ,business ,medicine.disease ,Biotechnology - Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.